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ABSTRACT 
The present thesis deals with the development of chromatography-mass spectrometry analytical 
methods for the analysis of target molecules in complex matrices. These compounds have 
different applications, ranging from nutraceutical to pharmaceutical or archaeological. Generally, 
the main aim was to provide accurate quantification of one or several analytes within real samples 
and then, in order to fulfil the requested standards, several efforts have been put on the 
development and validation of specific analytical methods, suitable for the system under 
investigation. The developed methods proved to be able to face the analytical challenges raised by 
the presence of complex matrices able to interfere with the accuracy of the result and the data 
interpretation. 
During the first year of PhD, my research focused on the analysis of glucosinolates, compounds 
occurring in the plants of Brassica order. Glucosinolate metabolism leads to compounds called 
isothiocyanates, known for their anticancer activity. Glucosinolates and isothiocyanates are 
compounds of strong interest for nutraceutical applications and functional food development, 
while their analysis is important for the evaluation of the product quality, especially in terms of 
available amount and stability. 
Another important project involved the in vivo evaluation of the biodistribution and metabolism of 
obeticholic acid in a cirrhosis induced rat model. Considering that obeticholic acid has been 
recently approved for the treatment of cirrhosis, the importance of this study resides in the 
necessity to assess a safety profile in case of administration to patients with liver diseases, where 
dangerous accumulation or unexpected metabolites might occur as consequence of the liver 
impairment. 
During my third year of PhD, I worked on the target analysis of different lipid classes in 
archaeological samples. The determination of specific biomarkers in archaeological finds, indeed, 
is important because it can address historical questions about past diets, ancient practices, but 
also vessel production and related use. 
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CHAPTER 1 
Glucosinolates and Isothiocyanates 
Every day, throughout food consumption, our organism encounters many natural substances 
having a well-defined biological action, which can be either positive or negative on our health. 
The strong awareness that specific edible substances can be very helpful for preventing the rising 
of many diseases has led the scientific research to focus on the study of the molecules responsible 
for the health benefit foods. 
The capability to combine normal foods with health promoting compounds has brought many 
food companies to invest huge amount of money in the development of the so-called “functional 
foods”, defined as aliments characterized by normal nutritional value and enriched with 
biologically active molecules. Following this lead, a great number of new functional foods has been 
introduced in the market, which is a very important step forward in the sector of the prevention. 
This chapter deals with a class of natural molecules, the glucosinolates (GLSs), and specific class of 
related metabolites, the isothiocyanates (ITCs). These molecules, found mainly in the plants of the 
Brassica order, are recognized to have a strong chemo preventive activity and are considered the 
main responsible for the health protective effects of some vegetables, like broccoli, rocket salad 
and cauliflower. 
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1.1 Introduction 
1.1.1 Structure and properties of glucosinolates 
Glucosinolates (GLSs) are natural compounds constituted by a (Z) β-tioglucoside, N-
hydroxysulphate group where the sulphur atom is linked to a lateral chain R (Figure 1). 
 
Figure 1. General structure of GLSs 
Glucosinolates are hygroscopic molecules presenting partition coefficients (logP) between -1 and -
3, they have good thermal stability (the pure solid form is does not degrade up to 110° C, while in 
matrix they are even more stable) and they naturally occur as completely water-soluble anions 
and partially soluble in methanol. So far, about 120 GLSs from more than 16 plant families have 
been identified. Among these, the most important and representative are Brasicaceae, 
Capparaceae and Caricaceae because of the high variety and amount of GLSs that they produce 
[1]. These vegetable families include vegetable like broccoli, rocket salad, cauliflower, mustard and 
turnips, whose organoleptic properties are strongly influenced by GLSs, stored as potassium salts 
inside the plant vacuoles. 
The family of GLSs has a great molecular variety due to the different lateral chain that may occur. 
These chains can be linear or branched and they often present double bonds, carbonylic, hydroxyl 
and thio-groups at different oxidation states. Anyway, the most studied GLSs, by virtue of their 
biological activity, are those with aliphatic, ω-methylthioalchilic, aromatic or heterocyclic lateral 
chains. 
Most plants produce a limited number of GLSs and their distribution, such as the qualitative and 
quantitative composition, in seeds, leaves, stems and roots is very variable. In the leaves, meanly, 
the GLSs amount is about the 1% of the dry weight, while in certain seeds the percentage can 
reach 10% [2]. The content can be influenced by other factors, such as the plant age, the 
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geographical origin, the soil fertility and composition, and the presence of particular bacteria and 
microorganisms. 
The biosynthesis of GLSs starts from glucose and some aminoacids [3]: aliphatic derivatives have 
as plausible precursors methionine, alanine, leucine, isoleucine and valine, while the aromatic 
ones are preceded by tryptophan, phenylalanine and tyrosine. The crucial steps in the synthesis 
are: lateral chain elongation (regulated by specific genes), glucone synthesis and structural 
modifications to the lateral chain. The first step in the synthesis is always a homologation of the 
aminoacid lateral chain by N-hydroxylation followed by decarboxylation, which lead to the 
formation of an aldoxime. This is oxidised to thiohydroxamic acid, which is then glycosylated at the 
sulphur atom to produce a desulphoglucosinolate. This one is finally sulphated by the 
desulphoglucosinolate sulphotranferase (PAPS) to produce the final GLS. The entire synthesis is 
simplified in Figure 2.   
 
 
Figure 2. Biosynthesis of GLSs 
The modifications to the lateral chain occur only after the GLS formation and they mainly involve 
oxidation of the methionine sulphur, desaturation and double bond hydroxylation. However, the 
exact mechanism by which these amendments are made has not been fully elucidated yet.   
1.1.2  Metabolism of GLSs 
Glucosinolate metabolism takes place when they encounter a specific type of hydrolytic enzymes, 
the myrosinases (MYRs) [4]. Myrosinases are vegetable endogenous thioglucohydrolase enzymes 
able to cleave the glucose group off from a GLS with the consequent production of a 
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thiohydroxamate O-sulfonate intermediate. This immediately evolves to a series of hydrolysis 
products, as reported in Figure 3 [5]. 
 
 
 
 
 
Figure 3. Metabolism of GLSs 
In normal conditions, GLSs and MYR are kept in different cellular compartments. They come into 
contact only during mechanical damage of the plant, for example during leaf chewing or by tissue 
damage caused by bruising or freeze–thawing during cultivation, harvest, shipping or handling [6], 
and it is then that, even in presence of minimum amount of water, the hydrolysis reaction takes 
place. 
The formation of a specific product after the hydrolysis depends on several factors: starting GLS, 
reaction conditions (pH, temperature, etc.), type of MYR and, eventually, presence of modifier 
proteins associated to MYR [5]. Indeed, there are different subclasses of MYR, type A-MYR (MYR 
A), type B-MYR (MYR B) and type C-MYR (MYR C). Normally, MYRs A act alone, while MYRs B and 
MYRs C are present as complexes with modifier proteins. These proteins can be of two different 
types: Epithiospecifier Proteins (ESPs) and Epithiospecifier Modifier Proteins (ESMs1). 
 
1.1.3  Isothiocyanates 
Isothiocyanates (ITCs) are a family of metabolites characterized by the presence of the –NCS 
functional group. Some of the most studied ITCs are reported in Figure 4. 
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Figure 4. Isothiocyanates best characterized 
Even though their general occurrence, ITCs are not present as such in the plants, but they are 
stored as GLSs, their metabolic precursors. Among all GLS metabolites, ITCs are the most studied 
and the most interesting due to their numerous health benefit properties. Their antibacterial [7], 
antifungal [8] and, above all, chemo preventive [9] and antioxidant [10] activities, in fact, have 
been extensively reported. 
Isothiocyanates present both a direct and indirect antioxidant activity. The direct one is mainly 
based on their capability to quench reactive radicals such as the hydroperoxides or other reactive 
oxygen species (ROS) [11]. This effect is mainly observed for ITCs having the sulphur atom on the 
lateral chain at low oxidation state. An important example is the erucin (ERN), the main metabolite 
of glucoerucin (GER), the main GLS of rocket salad. 
The indirect antioxidant activity is based on the induction of cytoprotective enzymes, like the 
NADPH quinone oxidoreductase 1 (NQO1) [12], which activate immune defences against the 
oxidant activity of many free radicals by promoting the synthesis of glutathione, enhancing 
xenobiotic elimination and inhibiting cytokine-mediated inflammation [13]. The most studied ITC 
for this indirect antioxidant activity is sulforaphane (SFN), the main metabolite of glucoraphanin 
(GRA), a much-diffused GLS among many Brassicaceae, like broccoli or cauliflower. In addition, 
SFN has been reported to inhibit the activity of phase 1 enzymes such as members of the 
cytochrome P450 (CYP) enzyme family [14], inflammatory processes [15] and histone deacetylase 
activity [16]. Furthermore, SFN alters cell proliferation and stimulates apoptosis [17]. 
On the other hand, not all GLSs appear to act equally and negative effects of some ITCs have been 
reported as well [18]. For example, the metabolites originated from neoglucobrassicin and 
epiprogoitrin have been reported to be, respectively, mutagen and goitrogenic. It is worth to 
highlight that GLS composition differ among the different Brassica vegetables on the basis of 
genetic, botanical, environmental and postharvest factors. In addition, the different stages in plant 
maturation play also a role in affecting the GLS pattern and content. 
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Taken together, consumption of GLSs cannot be considered to be protective in general, as many 
factors can affect the presence of a favourable or unfavourable pattern. Consequently, the 
analysis and understanding of biological effects is required, from which dietary recommendations 
for the prevention of cancer can be deduced. 
1.1.4  Influence of industrial processing on the GLS content 
Considering the high nutritional value possessed by GLSs, many functional products and 
nutraceuticals have been developed by enriching normal foodstuff with this class of molecules 
[19]. The main practical problem in the food production is related to the physical and thermal 
treatments of the raw materials used for this purpose [20]. Indeed, as these processes can 
influence the final GLS concentration, the best option is to reduce as much as possible the number 
of preparative/storage processes. 
The critical variables are: temperature, which is able to degrade GLSs and/or inactivate MYRs, the 
use of water for washing up, as it could solubilize the GLSs or hydrolyze them, and the loss of iron 
ions, ascorbic acid and other enzymatic cofactors. 
Another aspect that needs to be carefully considered is the presence of MYRs themselves. It is 
important to keep them in their active form, in order to allow the ITC formation, but it is also 
necessary to prevent their action before the consumption, as in this case the food would lose its 
beneficial properties. Isothiocyanates, indeed, are very reactive molecules and they quickly reduce 
their concentration once produced. So far, formulations containing both GLSs and MYRs revealed 
to be poorly effective, as substrate hydrolysis is very fast and the produced ITCs, because of their 
short half-life, are not efficiently absorbed. Better results were obtained by supplying these two 
components separately, for example using Arabic gum or maltodextrin capsules, in order slow the 
hydrolysis reaction down. 
An alternative approach is based on the use of GLSs without any MYR component, as intestinal 
microflora, although less efficient, possesses hydrolytic activity suitable for the GLS conversion 
into ITCs. Such a strategy is very useful for foods needing cooking before consumption, as in this 
case the loss of MYR activity would not represent an issue. This approach is supported by the 
findings reporting that, in absence of active MYR, high amounts of GLSs were recovered in the 
lower intestinal tract where they are hydrolyzed by the microflora in order to extract glucose [21]. 
Indeed, it has been demonstrated that high crucifer intake is associated to a different microbiome, 
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confirming that frequent consumption of GLS containing foodstuff is able to induce the production 
of bacteria with better hydrolytic properties [22]. 
1.1.5  Analytical methods for GLS and ITC determination 
Considering the importance of the system GLS/ITC, the qualitative and quantitative analysis of 
these classes of molecules has great importance in the food market, in order to assess the value of 
the product. 
One of the methods traditionally used for total GLS quantification is based on the determination 
of the glucose moles obtained after MYR catalyzed hydrolysis and after removal of the 
endogenous contribute [23]. Another method is based on the gravimetric titration of the sulphate 
ion (using barium chloride) obtained after MYR hydrolysis; the total GLS amount is then indirectly 
obtained from the determination of the residual barium in solution by X-ray emission 
spectroscopy [24]. 
The first method for the analysis of single GLSs was based on GC-FID after derivatization using TMS 
[25]. Unfortunately, GC methods have the drawback to be not suitable for thermally unstable GLS, 
such as the indoles, therefore HPLC soon became the most widely used instrumentation for GLS 
analysis. Nowadays the reference method for this purpose is the ISO 9167-1 procedure, which is 
based on the on column enzymatic desulphation of the GLSs into desulphoglucosinolates (DGLSs) 
and subsequent HPLC-UV analysis on a C18 column [26]. Although this method is the reference 
one, many drawbacks can be pointed out: the derivatization procedure is very long in order to be 
quantitative for all the GLSs (up to 24 hours), the UV detection is not very sensitive and selective, 
and the quantification is performed using the calibration curve of the desulphosinigrin 
(desulphobenzylglucosinolate is used as internal standard) and applying specific correction factors 
for each analyte. Due to all these limitations, nowadays the trend is to shift toward the use of 
mass spectrometry as detection technique. Indeed, many HPLC-MS/MS methods have been 
developed in order to analyze many GLSs and discover new ones in different matrices, such as 
rocket salad [27], broccoli [28], rape [29], cauliflower [30] and also functional foods [31]. 
As regards GLS breakdown products, ITCs and nitriles can be analyzed by GC, while HPLC with UV 
detection may be used for analysis of oxazolidinethiones and indoles. For confirmation and 
structural elucidation, both techniques can be coupled to mass spectrometry, which has proved to 
be a valuable tool in the structure identification of GLSs and related derivatives [32]. An elegant 
and sensitive method for the total ITC determination is based on the quantitative reaction with 
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1,2-benzenedithiole to form the 1,3-benzenedithiol-2-thione, which possesses a very high molar 
extinction coefficient and that is successively determined via spectroscopy [33]. 
Despite the high number of analytical methods available, several efforts have been made in the 
development of innovative procedures allowing the simultaneous determination of different 
classes of compounds in more complex matrices, like plasma or urine, suitable for in vivo 
pharmacokinetic and metabolism studies. 
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1.2 Aim and rationale 
Glucosinolates and, above all, ITCs have been object of many studies by virtue of their chemo-
preventive, anti-inflammatory and bactericide properties. Thanks to these, and considering the 
fast rising of the nutraceutical field, many functional foods enriched with this kind of molecules 
are available on the market or under development. Consequently, their low-cost synthesis or 
extraction and purification from natural sources is a theme of great actuality, especially within 
food companies. 
These compounds are not considered proper drugs and consequently they are not subjected to 
the long and demanding approval process requesting in vivo and in vitro studies of toxicity, 
pharmacodynamics and pharmacokinetics. However, it is still of great importance to accurately 
monitor their presence, stability and concentration not only in the final product, but in starting 
materials as well, in order to qualify the nutritional value of the product and to understand the 
effectivity of these molecules in a non-natural matrix. 
The only reference method available for GLS analysis is the ISO-9167-1, which requests the 
enzymatic conversion of GLSs into DGLSs prior their quantification by HPLC-UV. This method 
results to be time demanding, relatively expensive, poorly sensitive and many pre-analytical steps 
are requested. Many HPLC-MS methods are available to overcome these limitations, but none of 
them has been fully validated for the GLS analysis in functional foods. Additionally, all these 
methods target only the GLSs, while for ITC analysis a second analysis is always requested, making 
the comprehensive profiling of both classes longer. The possibility to achieve quantitative 
information of both of them in the same analysis represents an important tool in the design of 
these products and the study of GLS stability and biotransformation. 
On these basis, the aim of this research project was to develop and validate, in accord to the 
international guidelines [34], an HPLC-ES-MS/MS for the simultaneous analysis of specific GLSs and 
the derivate ITCs in different vegetable matrices and functional GLS enriched bakery products. The 
target compounds of this study were GRA, GER and the relative ITCs: SFN and ERN (Figure 5), as 
they were the main nutraceuticals used for the functional food production and the most abundant 
in the starting materials. With this aim, extraction procedures were optimized in order to 
effectively recover the bioactive molecules from more complex matrices, such as bakery and food 
products. 
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Figure 5. Main GLSs in E. Sativa (rocket salad) seeds and related ITCs 
The final aim was to develop a direct, robust, fast and reliable method potentially exploitable in 
the food industry for the simultaneous evaluation of the availability of GLSs and related active 
metabolites during the entire chain of production, from the starting materials to the final product. 
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1.3 Materials and methods 
1.3.1  Chemicals 
Glucosinolates GRA and GER were extracted and purified starting, respectively, from Brassica 
Oleracea [35] and Eruca Sativa [36] seeds. Briefly, seeds were pulverized, and the oil removed 
using hexane. The residue was treated with refluxing ethanol at 70 °C in order to rapidly 
deactivate MYR. The mixture was then homogenized, centrifuged and the supernatant subjected 
to ionic exchange chromatography, in order to obtain fractions rich in GLS. The GLS purity was 
improved by gel-filtration performed using an XK 16/60 column packed with Sephadex G10 
chromatography media (Amersham Biosciences), connected to an FPLC System (Pharmacia). 
Fractions containing pure GLSs were pooled and freeze-dried. The purity of GLSs assessed by HPLC 
resulted to be 99% (peak area based) and 95% on weight basis. 
Isothiocyanate SFN and ERN standards were purchased from Santa Cruz Biotechnology (Dallas, 
Texas). 
Methanol (MeOH) and acetonitrile (ACN) of HPLC-grade (Lichrosolv®) were purchased from Merck 
(Darmstadt, Germany). Formic acid (98% purity) and ethanol (99.8%purity) were purchased from 
Fluka (Buchs, Switzerland). Water of HPLC-MS grade (Millipore) was produced using the 
depurative system Milli-Q Synthesis A 10 (Molsheim, France). Other solvents were all of analytical 
grade. 
Stock standard solutions of GRA and GER were prepared in water/MeOH 50:50 (v/v) at 
concentration of 5 mg/mL, while SFN and ERN standard stock solutions were prepared in 
acetonitrile at concentration of 5 mg/mL. These stock solutions were aliquoted and stored at −20 
°C to minimize potential analyte degradation. Working standard solutions (WSs) containing both 
GLSs and ITCs were freshly made by appropriate dilution of the stock solutions in acetonitrile in 
the range 0.5–200 g/mL and stored at +4 °C to be used at most for a week. Calibration solutions 
in the range 0.05–20 g/mL were freshly prepared before the analysis by 1:10 dilution of the WSs 
using a mixture of H2O-ACN (95:5). Quality control samples (QCs) containing the four analytes 
were obtained in a mixture of H2O-ACN (95:5) at concentrations 1.7μg/mL, 6.7μg/mL e 16.7μg/mL. 
These samples were used for the method validation or injected randomly during the analysis in 
order to control the normal behaviour of the analytical system. 
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1.3.2  Instrumentation 
The chromatographic apparatus consisted of a Waters Alliance 2690 Chromatograph (Milford, MA, 
USA) with 120 position autosampler and thermostat coupled with a mass spectrometer triple 
quadrupole and electrospray interface (QUATTRO LC, Waters). The column was a WATERS X-select 
CSHTM C18 5.0 m (2.1 mm × 150 mm). 
1.3.3  HPLC-ESI-MS/MS conditions 
Chromatographic separation was achieved using a reversed phase C18 column. The mobile phase 
was constituted by HPLC grade water with 0.5% formic acid (A component) and ACN with 0.5% 
formic acid (B component). Different LC gradients were evaluated during the method 
optimization. The best separation was obtained with the following gradient of the B component: 3 
min 0%, 7 min at 5%, 4 min at 24%, 4 min at 50%, 7 min at 80%, 10 min at 5% (total run time 35 
min) at 0.15 mL/min flow rate. Each variation in the eluent composition was linear, except for the 
last step in which the composition changed instantaneously. The column was maintained at 30 °C 
and the injected sample volume was 5 L. In these conditions, the mean retention times were: 
GRA 6.6 ± 0.2 min, SFN 16.9 ± 0.2 min, GER 18.3 ± 0.1 min and ERN 26.5 ± 0.2 min. The total ion 
chromatogram (TIC) with all the analytes is reported in Figure 6.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Total ion current chromatogram reporting the HPLC separation on a C18 column 
of GRA (6.6 min), SFN (16.9 min), GER (18.3 min) and ERN (26.5 min)  
The column effluent was introduced into the ESI source, operating in negative ion mode for GLS 
(GRA and GER) and positive ion mode for ITC (SFN and ERN), connected to a triple quadrupole 
mass spectrometer operating in the multiple reaction monitoring (MRM). In Table 1 the MS/MS 
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experimental conditions have been reported, tuned by direct analyte infusion (20 g/mL of each 
analyte; 2 mL/h infusion rate) and afterwards by on column injection of each individual compound 
and a mixture of all of them. Two signals in extracted ion chromatogram (EIC) were monitored for 
each compound. The most intense was used for the quantification, the second one for the 
compound identity confirmation. For GRA and GER the quantification transitions were, 
respectively, 436.1 > 436.1 and 420.1 > 420.1, corresponding to the deprotonated molecules, 
while for the confirmation the fragmentation reactions used were, respectively, 436.1 > 97.1 and 
420.1 > 97.1, in which the fragment at m/z 97.1 corresponded to the bisulphate group. For SFN 
the quantification transition was 178.2 > 114.2 consisting in the loss of the CH3SO group, while the 
qualification reaction was 178.2 > 72.2 corresponding to ion SCN-CH3+; for ERN, the transition 
162.2 > 103.2, corresponding from the loss of the SCN group, was used for the quantification, and 
the transition 162.2 > 162.2 for the confirmation. 
Table 1. MS ionization and detection parameters of GRA, GER, SFN and ERN 
 GRA GER SFN ERN 
Ionization mode Negative Negative Positive Positive 
Capillary voltage (KV) -2.3 -2.3 +2.3 +2.3 
Cone voltage (V) +35 +35 -15 -15 
Source temperature (°C) 130 130 130 130 
Desolvation temperature (°C) 200 200 200 200 
Collision gas Argon Argon Argon Argon 
Quantification reaction 436.1 > 436.1 420.1 > 420.1 178.2 > 114.2 162.2 > 103.2 
Confirmation reaction 436.1 > 97.1 420.1 > 97.1 178.2 > 72.2 162.2 > 162.2 
 
1.3.4  Method validation 
Method validation was performed according to ICH guidelines, determining selectivity, limit of 
detection (LOD), limit of quantification (LOQ), calibration range, precision, accuracy and matrix 
effect. 
1.3.4.1  Selectivity 
The selectivity indicates the capability of a method to discriminate the analytes in respect to other 
components in the matrix. Selectivity was evaluated comparing the chromatograms obtained from 
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standard solutions, sample solutions and spiked sample solutions. This procedure was necessary 
for selectivity evaluation, as no blank sample (analyte free) was available. 
1.3.4.2  Calibration range 
The calibration range is related to the amount of analyte present in the sample. Ideally, a 
calibration range must be comprised between, respectively, the 80% and 120% of the minimum 
and maximum analyte concentrations in the real samples and should exhibit linearity between 
instrumental response and concentration over the selected range. In this case, quantification was 
performed by construction of seven-point calibration curves in the calibration range 0.05-20 
μg/mL, according to the specific compound to be determined. Specifically, for GRA, GER and SFN 
the calibration range was 0.05–20 g/mL, while for ERN was 0.5–20 g/mL.  
1.3.4.3  Precision and accuracy 
The precision and the accuracy define, respectively, the reproducibility of an analytical 
determination (how good is the accord between a series of repeated analysis), and the goodness 
of such determination (how close is the obtained result to the “real value”). 
The precision is defined as variation coefficient (CV%): 
 
The accuracy is defined as bias%: 
 
According to the international guidelines, both precision and accuracy must be determined, at 
least, in triplicate and on three different concentration levels within the calibration range. 
1.3.4.4  Limit of detection and quantification 
The LOD defines the minimum analyte concentration that can be reasonably distinguished from 
the background noise. The LOQ, on the other hand, is defined as the minimum analyte 
concentration that can be measured with satisfying precision and accuracy. Although at least 
three methods for the LOD/LOQ determination are accepted, the most used, above all for 
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analytical methods exhibiting baseline, is based on the signal to noise ratio (S/N). Specifically, LOD 
and LOQ are defined as the minimum concentrations giving, respectively, a S/N of 3 and 10. 
1.3.4.5  Matrix effect 
The matrix effect (ME) is defined as the increase or decrease in the instrumental response referred 
to an analyte as consequence of the presence of other components in the real sample. Matrix 
effect was evaluated for all analytes as ratio between the absolute matrix effect and the peak area 
of standard sample in mobile phase. Absolute matrix effect was calculated as difference between 
the peak area of the standard sample in matrix and the peak area of standard sample in mobile 
phase. The endogenous contribute for each analyte was subtracted from the peak area of 
standard sample in matrix. Matrix effect was expressed as percentage (EM%), so that values close 
to 0% indicated absence of ME, while higher or lower values indicated, respectively, positive or 
negative ME. 
1.3.5  Samples and experimental procedures 
1.3.5.1 Material characterization 
An E. sativa ecotype (Nemat) selected as potential source of GER and GRA was used to produce a 
pressure defatted oilseed meal (DSM) as a food-safe organic material for the GLS enrichment of 
bakery products, to realize functional foods for the nutraceutical target. The addition of minimum 
amounts of broccoli flour as additional source of GRA and for the definition of the product taste 
was possible as well. The new functional bakery products have been developed basing also on 
recent toxicological studies showing how GLSs and ITCs, at doses lower than 100 mol/day, lack of 
toxicity and reveal no evidence of systematic, clinically significant adverse events [37]. E. Sativa 
seeds were defatted by an endless screw press in a temperature and pressure-controlled 
procedure [38]. The E. sativa DSM was characterized for moisture, nitrogen, residual oil and GLS 
content. In particular, the moisture content was determined by evaluating the difference between 
its weight before and after oven-drying at 105 °C for 12 h; nitrogen content was determined by 
the Kjeldhal method [39], using a Tecator digestion system and an automatic Büchi distillation unit 
(B 324); residual oil was extracted with a Soxhlet apparatus and characterized for its fatty acid 
composition by the UNI EN ISO 5508 method [40]. Myrosinase activity was also determined by the 
pH-stat technique [41]. The assays were carried out in triplicate by loading 300 mg of DSM in 15 
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mL of 1% NaCl into the reaction cell at 37 °C. The reaction was started by adding 0.5 mL of 0.5 M 
sinigrin solution, after 8–10 minutes of conditioning, maintaining the starting pH constant. One 
enzyme unit (U) corresponded to 1 mol/g DSM of sinigrin transformed in 1 minute. An E. sativa 
meal extracted overnight at room temperature with n-hexane (1:10 w/v) in a rotary shaker, has 
been used as reference for maximum MYR activity. Two different defatting procedures were 
tested: a low temperature-pressure extraction (40–65 °C temperature range), and a high 
temperature-pressure extraction (initial temperatures higher than 100 °C). Recipes and final food 
products were produced in the R&D and QA of Colussi-Group (Milan, Italy) by adding 1% of DSM 
to a standard cracker mixed with wheat flour baked at 200 °C in industrial plant. The addition of 
active MYR in the cooling phase of production by using mustard meal was also explored. Further 
information on the recipes is commercially confidential and their property is of Colussi-Group. 
1.3.5.2 Extraction of GLSs and ITCs 
Analytes from DSM were extracted by following the ISO 9167-1 method with some minor 
modifications [42]. Briefly, 300-500 mg of DSM were pulverized to a fine powder, incubated in 
thermal bath at 90 °C for 10 minutes in 4 mL EtOH 70% and then subjected to sonication bath for 
30 minutes. Extracts obtained were centrifuged for 30 minutes at a speed of 39800 rpm at a 
temperature of 4 °C and then filtered. The remaining flour was washed with 4 mL EtOH and 
filtered. The extracts were combined for the determination of the final volume. 
For an effective extraction from the bakery products, a combined procedure of sonication and 
microwave extraction was carried out. Four grams of crackers finely pulverized in 25 mL of 70% 
ethanol were sonicated 30 min in a Sonica Sweep System (Soltec) bathroom at 40 kHz. They were 
then extracted in Teflon vessels with the MARS system (CEM Corporation) setting 400 W as 
maximum power, heating ramp at 80 °C in 3 min and extraction at 80 °C for 10 min. The extracts 
were centrifuged 30 min at 25.900 rpm at a temperature of 4 °C (Beckman J2-MC centrifuge, rotor 
j14) and filtered (qualitative paper Whatman # 4, Sigma Aldrich) in a 50 mL graduated cylinder. 
The residue was re-extracted and the second extract was centrifuged, filtered and combined to 
the first for the determination of the final volume. 
1.3.5.3 Glucosinolate analysis by ISO 9167-1 method 
Glucosinolate content was evaluated by HPLC-UV analysis of DGLSs using de ISO 9167-1 method 
[26]. Briefly, the extracts obtained according to the procedure reported above were subjected to 
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enzymatic desulfation by introducing 1 mL of extract containing the GLSs into microcolumns (8 
mm internal diameter from BIORAD) filled with 0.5-1.0 mL DEAE Sephadex A-25 resin (Pharmacia), 
previously conditioned at pH 4.0 or pH 5.6 with 20 mM acetate buffer, depending on the material 
that has to be analyzed. After sample loading, the resin is washed with the same buffer to remove 
non-charged molecules, while the GLSs, anionic compounds, are immediately bound at the top of 
the column. A suitable quantity of purified sulfatase (about 0.10 mL, 0.28 U/mL) is then loaded 
into the column; as a result of sulfatase action, the sulphate group of the GLSs is removed and the 
DGLSs are eluted with water (3 mL) after about 12-24 hours. The analysis of DGLSs was performed 
using a Hewlett-Packard chromatograph 1100 equipped with a diode array detector and 
ChromSep HPLC column SS (250 mm × 3.0 mm) and a ChromSep guard column Intersil 5 ODS-3 
(Varian). The column was eluted at a flow rate of 0.8 mL/min with aqueous acetonitrile (solvent A: 
water; solvent B: acetonitrile 25%in water) at 30 °C following the program: 1 min 99% A; 22 min of 
linear gradient up to 88% B; 5 min of linear gradient up to 100% B; 3 min of linear gradient up to 
100% A. The DGLSs were detected monitoring their absorbance at 229 nm. 
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1.4 Results and discussion 
1.4.1 Chromatographic and MS condition optimization 
Preliminary experiments using standard solutions of the analytes were performed in order to 
select the optimal separation conditions. The column chosen was a WATERS X-select CSH TM C18 
5.0 m (2.1 mm × 150 mm), as, to date, no other stationary phases giving better chromatographic 
results have been reported; besides, the small internal diameter ensured the possibility of using 
low flow rates with a reduction of mobile phase volume. Mobile phase composition was chosen in 
order to improve the chromatographic separation and the detection sensitivity. An “ion pairing 
reagent” was used to enhance the ionization process occurring at the ES interface and to improve 
the chromatographic interactions between analytes and stationary phase. At this regard different 
amounts of trifluoroacetic acid, acetic acid and formic acid into mobile phase were studied. Best 
results, in terms of peak shape, sensitivity and noise suppression, were obtained using phases 
acidified with 0.5% formic acid. The choice of acetonitrile as organic component instead of 
methanol or methanol/acetonitrile mixtures was made in order to reduce elution time without 
any loss of resolution power or ionization efficiency. Different flow rates, in the range 0.10–0.15 
mL/min, were tested as well in order to reach the best compromise in terms of peak symmetry, 
resolution and time of analysis. It was observed that the increase of flow rate caused a reduction 
of the peak width and analysis time, without significantly affecting resolution and selectivity. So, a 
flow rate of 0.15 mL/min was considered optimal for our purposes. As regards the temperature 
influence, different column temperatures were tested in the range 20–60 °C. In this range, a slight 
reduction of retention times and peak symmetry were observed with temperature increase and, 
for this reason, the column temperature was set at 30 °C. In the best conditions, the 
chromatographic run time was 35 min, in order to obtain a versatile method that can be 
successfully applied to different complex matrices containing GRA, GER, SFN and ERN but also a 
wider range of GLSs. For example, analyzing a real sample of broccoli extract, this method allowed 
the separation of more than seven GLSs (Figure 7). Glucosinolates are natural molecules all 
characterized by the presence of the sulphate group, whose high acidity makes them occur as 
negatively charged molecules and therefore easily detectable in ES negative ion mode. 
Isothiocyanates, on the other hand, have no acidic groups and they respond only in positive 
ionization mode. For this reason, an MRM program constituted of two different detection 
windows, one operating in negative and the other in positive mode, was set making possible the 
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simultaneous analysis of GLSs and ITCs. Moreover, MRM detection mode ensured high sensitivity 
and specificity, reducing the interferences and increasing the signal to noise ratio. 
 
 
 
Figure 7. Chromatogram obtained from broccoli extract. Based on literature data and m/z 
values, GLS identified are: glucoiberin (5.5 min), glucoraphanin (6.4 min), epiprogoitrin 
(7.5 min), gluconapin (15.3 min), glucobrassicin (21.2 min), 4-metoxyglucobrassicin (22.4 
min) and neoglucobrassicin (23.8 min)  
1.4.2 Method validation 
The developed method for the analysis of GRA, GER, SFN and ERN fulfils all the standard 
requirements of the ICH Guidelines [34] including the sample clean-up and pre-analytical 
treatment. 
1.4.2.1 Selectivity 
Selectivity was established by injection of single standards and of mixtures of them, in order to 
determinate their retention time. The comparison between standard solutions and samples 
fortified with known amounts of analyte, using MRM and EIC modes, showed absence of any 
interference in the matrices. 
1.4.2.2 Calibration curves 
Seven-point calibration curves ranging from 0.05 to 20 g/mL for GRA, GER, SFN and from 0.5 to 
20 g/mL for ERN, based on peak areas and without internal standard, were used for the 
quantification, as described in Section 2.4. As no significant matrix effect was observed (Matrix 
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Effect < 10%), as described in Section 1.4.2.5, calibration curves were obtained in mobile phase, 
allowing a more accurate quantification than methods using matrix-matched standard curves. 
Correlation coefficients for all analytes were ≥0.998, meaning a good linearity in the calibration 
ranges and making possible not to use any internal standard. 
1.4.2.3 Precision and accuracy 
Precision (SD%) and Accuracy (Bias%) values, determined in intra-day and inter-day assays, as 
described in Section 1.3.4.3, were less than 10% for all GLSs and ITCs studied. These results 
indicate that the method fulfils the ICH criteria, being sufficiently precise and accurate, and 
although its use is recommended, internal standard is not necessary. 
1.4.2.4 Limit of detection and quantification 
Limit of detection and quantification were determined as described in Section 1.3.4.4. Limit of 
detection values were 10 ng/mL (GRA), 1 ng/mL (GER), 1 ng/mL (SFN) and 200 ng/mL (ERN). Limit 
of quantification values were 20 ng/mL (GRA), 2 ng/mL (GER), 2 ng/mL (SFN) and 400 ng/mL (ERN). 
1.4.2.5 Matrix effect 
Matrix effect percentage values close to 0% showed absence of matrix effect, values higher and 
lower than 0% indicated, respectively, ionic increase (positive matrix effect) or ionic suppression 
(negative matrix effect). Matrix effect was evaluated analyzing in triplicate three different 
concentration levels, using the same QCs reported in Section 1.3.1. Diluting 1:10 (v/v) cracker or 
vegetable extracts, matrix effect observed was less than 10% at all concentrations levels for all the 
analytes.  
1.4.3 Mass spectrometry analysis of GLSs and ITCs 
Glucosinolates are naturally negatively charged molecules by virtue of the presence of the 
sulphate group, consequently they are easily detected in negative ionization mode. Different 
attempts were made in order to analyze them in positive ionization mode, but none of them 
proved to be effective. Isothiocyanates, on the other hand, have no acidic groups and the positive 
ionization mode revealed to be the best choice for their analysis. 
The optimization of MS conditions has been carried out throughout the tuning of the electrospray 
ionization parameters: capillary and cone voltages, collision energy and source temperature. The 
 26 
proper tuning of these parameters allowed us to gain high current intensities for a sensitive 
detection of the compounds.  
1.4.3.1 Mass spectrometry characterization of GLSs 
Electrospray ionization in negative mode of GLSs affords [M - H]- ions which have been used for 
the quantification of these analytes. Besides, the use of tandem mass spectrometry with low 
collision energies in MRM acquisition mode ensures cleaner spectra compared to single ion 
recording (SIM), without significant loss in sensitivity of the deprotonated molecule. The increase 
in collision energy, on the other hand, yielded extensive fragmentation, providing structural 
information and allowing to select secondary transitions for a further confirmation of the selected 
compound. On these basis, direct infusion was performed for each single standard and the most 
intense ion produced in the electrospray source was selected and furtherly subjected to tandem 
mass spectrometry characterization at different collision energies, with the aim to select the best 
conditions required for the analysis. 
In Figure 8, GRA tandem MS spectrum of the precursor ion [M - H]- (m/z 436.1) and the assumed 
fragmentation mechanism are reported. 
     
Figure 8. Tandem MS spectrum of the GRA precursor ion [M - H]- (m/z 436.1) 
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In the GRA tandem MS spectrum, the base peak at m/z 436.1 corresponds to the [M - H]- ion, but 
other three main fragments can be observed at m/z 372.1 (obtained from the loss of the neutral 
fragment CH3SOH), m/z 178.1 (due to the successive loss of the thioglucose moiety) and m/z 97.1 
(corresponding to HSO4- ion) [27]. Consequently, in the MRM program, the transition 436.1 > 
436.1 at low collision energy was selected for the quantification, while the transition 436.1 > 97.1 
at higher collision energy for the confirmation. 
In Figure 9, GER tandem MS spectrum of the precursor ion [M - H]- (m/z 420.1) and the assumed 
fragments are reported.  
 
Figure 9. Tandem MS spectrum of the GER precursor ion [M - H]- (m/z 420.1) 
Compared to GRA, GER shows a more limited fragmentation. The [M - H]- (m/z 420.1), besides the 
bisulphate ion (m/z 97.1), affords only peaks at m/z 259.1 and 195.1, whose hypothesized 
structures are showed in Figure 9 [27]. Consequently, in the MRM program, the transition 420.1 > 
420.1 at low collision energy was selected for the quantification, while the transition 420.1 > 97.1 
at higher collision energy for the confirmation. 
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1.4.3.2 Mass spectrometry characterization of ITCs 
Electrospray ionization in positive mode was selected as the best option for ITC detection. 
Similarly to GLSs, the MRM acquisition mode was selected in order to improve the sensitivity of 
the method. Consequently, in order to determine the best transitions for the quantification and 
the confirmation, the most intense ion produced in the electrospray source was selected and 
subjected to tandem mass spectrometry analysis at different collision energies to properly tune 
the analysis conditions. 
Sulforaphane shows the MS/MS spectrum of the precursor ion [M + H]+ reported in Figure 10. 
 
Figure 10. Tandem MS spectrum of the SFN precursor ion [M + H]+ (m/z 178.2) 
The tandem MS spectrum obtained after isolation of the [M + H]+ ion of SFN (m/z 178.2) shows 
three main fragments. The ion having m/z 118.2 corresponds to the loss of the SCN group, while 
signals at m/z 114.2 and 72.2, are related first to the loss of the CH3SO group and to the successive 
cleavage of a CH2CH2CH2 moiety. In this case, the collision energy used to induce the 
fragmentation was high enough to lead to a very low intensity of the protonated molecule [M + 
H]+ in favor of the other fragments, definitely more intense. Consequently, in the MRM program, 
the transitions 178.2 > 114.2 and 178.2 > 72.2 were selected, respectively, for the quantification 
and the confirmation. 
Erucin shows the MS/MS spectrum of the precursor ion [M + H]+ reported in Figure 11. 
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Figure 11. Tandem MS spectrum of the ERN precursor ion [M + H]+ (m/z 162.2) 
In this spectrum, the two most intense fragments of the precursor ion [M + H]+ (m/z 162.2) were 
tentatively identified as reported in Figure 11. In the end, the transitions 162.2 > 103.2 and 162.2 > 
162.2 were selected, respectively, for the quantification and the confirmation.     
1.4.4 Design of GLS enriched bakery products 
E. sativa DSM was derived from a pressing pilot extraction plant [38]. It showed a moisture of 7.4%, 
31% proteins, and a 20.5% residual oil content with 37% erucic acid. Food-grade products 
containing rapeseed oil are regulated to a maximum of 2% [43] and 5% [44] erucic acid in the USA 
and in the EU, respectively. Defatted seed meals produced starting from E. Sativa by this way can 
be considered safe for food enrichment up to a maximum concentration of 25%. The GLS content 
was evaluated both by HPLC analysis of DGLSs and by HPLC–ES-MS/MS as described above. For 
vegetable samples, it has been demonstrated a very good agreement with the described HPLC–
ESI-MS/MS method (Table 2), with the advantage of a reduction in the analysis time from two 
days to 35 min. The maximum activity of MYR was 24 ± 3 U for E. sativa DSM defatted by Hexane. 
The DSM produced for food enrichment showed a residual activity (11 ± 2 U) for the low 
temperature pressure extracted DSM, and no residual enzymatic activity for the high temperature 
pressure extracted DSM. The peculiarity of the produced DSMs is the high content in GLSs and the 
presence of only GLSs actually considered safe as food additive, with beneficial effects as widely 
 30 
described in the literature [37,45]. Glucosinolates, indeed, cannot be considered to be protective 
in general. Depending on the species and growth phase, plants may harbor a favorable or 
unfavorable pattern of GLSs. It is noteworthy to highlight two GLSs present in broccoli: 
epiprogoitrin and neoglucobrassicin. The first one is known to be a goitrogenic while the second is 
a potential mutagenic [18]. Both DSMs were able to maintain a good concentration in GLSs even 
after pressure oil extraction and heat treatments. In addition, this method proved to be suitable 
for the separation and analysis of different and more complex matrices such as broccoli in which 
several GLSs are present, as described above (Figure 7). 
Table 2. Values of GLS content in E. Sativa DSM expressed as mean ± standard deviation of three 
replicates 
 HPLC-ES-MS/MS  
(mol/g) 
ISO 9167-1  
(mol/g) 
(MYR+) DSM 
GRA 0.44 ± 0.01 0.60 ± 0.10 
GER 89.8 ± 2.2 92.2 ± 7.4 
Total GLSs 90.2 ± 2.2 92.8 ± 7.4 
(MYR-) DSM 
GRA 0.47 ± 0.01 1.7 ± 0.8 
GER 74.6 ± 2.0 72.0 ± 3.0 
Total GLSs 75.1 ± 2.0 73.7 ± 3.0 
 
1.4.5 Quality control and improving of GLS enriched bakery products 
The DSM with no MYR activity (MYR−) has been chosen to proceed with the development of the 
enriched bakery products. Indeed, as shown in Figure 12, the final bakery products made of DSM 
with MYR- afforded definitively higher amounts of GLSs than the recipe with MYR+. This 
demonstrates that during the preparation and baking of the product, degradation of GLSs to form 
ITCs occurs. Unfortunately, ITCs were not detected during the analysis, likely because the 
conditions experienced during the preparation were unfavorable to allow the persistence of these 
compounds until the analysis.  
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Figure 12. HPLC-ESI-MS/MS analysis of functional bakery products enriched with E. sativa 
DSM with active MYR (green) and MYR free (grey) 
The selected DSM would be theoretically able to ensure an intake of GLSs up to 75 mol/100 g of 
product, adding only 1% of E. sativa DSM to standard industrial recipes of crackers after baking at 
180 °C. The extraction of GLSs from bakery products, which proved to be a more complex matrix 
than vegetables, was very challenging and constituted one of the critical steps in the method 
optimization. Indeed, the typical extraction of GLSs with heated solvents, as reported in the ISO 
9167-1 protocol, was not sufficient for efficiently extracting GLSs from bakery products (Fig. 13).  
 
___ active myrosinase 
___ myrosinase free 
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Figure 13. HPLC analysis of DGLSs of E. sativa DSM enriched crackers. (A) GLS extraction 
as described in ISO 9167-1, (B) GLS optimized extraction via a sonication step followed by 
microwave assisted extraction 
The extraction strategy was optimized combining known methods for the extraction of GLSs, 
particularly GER from E. sativa seeds [46]. Specifically, a combined pre-sonication and microwave 
assisted extraction (MAE) allowed a recovery of 95.9% of total GLSs, as reported in Table 3.  
Table 3. Recovery (%) of total GLSs from enriched bakery products under different extraction 
procedures, as evaluated by HPLC–UV analysis of DGLSs 
GLS extraction Total GLSs (g/100 g) Recovery (%) 
ISO 9167-1 10.0 ± 0.3 14 ± 1 
MAE, 70% ethanol 29.0 ± 0.9 52 ± 4 
Pre-sonication, MAE, 70% ethanol 71± 4 96 ± 11 
 
The GLS content was evaluated both by HPLC–UV analysis of DGLSs and by HPLC–ES-MS/MS and, 
also for a complex matrix as a bakery product, it has been demonstrated a very good agreement of 
data for both target GLSs (Table 4). 
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Table 4. GLS content in E. Sativa DSM enriched cracker, determined both by HPLC-ESI-MS/MS and 
HPLC-UV 
 HPLC-ESI-MS/MS of intact GLSs HPLC-UV of DGLSs 
GRA (mol/100 g) 3.0 ± 0.1 1.3 ± 1.0 
GER (mol/100 g) 68 ± 3 70 ± 3 
Total GLS (mol/100 g) 71± 3 71 ± 4 
Recovery (%) 94 ± 6 96 ± 11 
 
It is interesting to note that this result was achieved in HPLC–ES-MS/MS without any pre-cleaning 
of samples. This is very important because it allows to bring down a significant cost deriving from 
the pre-analytical procedure, especially if considered within an industrial point of view where the 
quality control needs to be performed as cost-effectively as possible. Furthermore, still from an 
industrial point of view, only 5% of the total GLS has been lost in the process of mixing and 
cooking, thus confirming the potential use of Brassicaceae meals in nutraceutical products. 
Probably a minimal content of GER was oxidized to the GRA in the whole industrial process. The 
recipe for the production of crackers enriched with E. sativa DSM was defined with the aim of 
maximizing the yield of intact GLSs in the dough characterized from the absence of activity of the 
enzyme (MYR− DSM). Such a conceived product may exert its beneficial effects only after the slow 
hydrolysis of GLSs to ITCs by intestinal microbiome. The addition of active enzyme (MRY+ DSM) to 
the dough may be possible in the cooling phase of production using mustard seed meal. In this 
case, it is reasonable that no GLS degradation occurred, being the enzyme added to a completely 
dried product.  On the basis of this last concept, the developed HPLC-ESI-MS/MS method was 
evaluated also for the simultaneous determination of ITCs and GLSs during a simulated chewing 
process using artificial saliva (Figure 14). 
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Figure 14. HPLC-ESI-MS/MS analysis of functional bakery products enriched with E. sativa 
DSM with active MYR subjected to a simulated chewing process with artificial saliva  
This experiment was performed in order to verify the effectiveness of using a bakery product with 
active MYR in producing the bioactive compounds during the consumption of the product. Results, 
as reported in Table 5, shows that small amounts of ITCs might be formed in the chewing process 
already, opening a new lead for the exploitation of this strategy for a slow and controlled release 
of ITCs, independent from the action of the microbiome. 
Table 5. GLS and ITC amounts obtained from chewing simulated extraction from crackers 
GRA (g/100 g) GER (g/100 g) SFN (g/100 g) ERN (g/100 g) 
1.2 ± 0.1 16.5 ± 1.0 0.1 ± 0.0 18.2 ± 1.1 
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1.5 Conclusions 
E. Sativa contains a wide range of compounds with nutraceutical and organoleptic properties and 
is used, since ancient times, in traditional medicine. Recently E. sativa has appeared to be an 
interesting industrial non-food crop, due to its wide climatic and agronomical adaptation and to 
the good yield of oil with high erucic acid content, which makes it a promising alternative for 
energy and biolubricant chain. E. sativa DSM represents a co-product of the biodiesel chain, 
particularly rich in high added value compounds such as GLSs, whose valorization makes the entire 
chain environmentally and economically sustainable. 
In this context, an HPLC–ESI-MS/MS method for the simultaneous determination of GLSs and ITCs 
has been developed and validated according to ICH guidelines. The method showed to be robust 
and selective, precise and accurate, and permits the quantification of the GLSs and ITCs during all 
various stages of the industrial process from biomass evaluation to GLS-based functional food 
production. This method was compared with the ISO 9167-1 reference method for GLS analysis 
and the results were in good agreement, with the great advantages of much shorter analysis time 
and the total absence of any pre-analytical derivatization steps, which are required in the 
reference method. Concerning ITC characterization, the most widely HPLC method involves their 
cyclocondensation with 1,2-benzenedithiole to give1,3-benzodithiole-2-thione which shows a high 
molar extinction coefficient at a relatively long wavelength (ε = 23,000 M−1cm−1 at 365 nm), thus 
enabling ITC determination in HPLC–UV coupled to a previous solid phase extraction of 1,3-
benzodithiole-2-thione via a reversed phase cartridge from samples with ITC content as low as 1 
pM [33]. The method of derivatization always implies an increase in working times and, in this 
case, the use of reagents toxic to the environment (German Water hazard class 3 for 1,2-
benzenedithiole) and probably to humans. The new HPLC–ESI-MS/MS method could replace not 
only the ISO 9167-1 protocol currently used, but also all the HPLC–UV methods used for the 
qualitative and quantitative determination of ITCs [47]. The new method is a potent tool for 
potential application in industrial health food production, facilitating the design and optimization 
of new containing GLS/ITC functional foods starting from the evaluation of the best biomasses to 
the final product. The thermal stability, enzymatic metabolism and all the other parameters 
affecting the stability of these molecules can be then easily quantified, allowing a faster and 
predictive design of new functional foods.
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CHAPTER 2 
Obeticholic acid in decompensated liver cirrhosis 
Bile acids (BAs) are naturally occurring compounds synthetized in vivo from cholesterol. The most 
recognized function of BAs is their ability to dissolve lipophilic molecules and transport them 
throughout the systemic circulation. This is related to their amphipathic structure which leads to 
the formation of micelles in association to phospholipids in biliary fluid, where BAs are present at 
millimolar levels, then beyond their critical micellar concentration (CMC). Recently, the role of BAs 
as natural agonists of Farnesoid X receptor (FXR) and TGR5 has been reported, opening the lead to 
new insights in BA physiological functions. Indeed, considering that these two receptors are 
involved in several hepatic diseases and metabolic disorders, new semisynthetic analogues of 
endogenous BAs with improved binding potency towards FXR and TGR5 have been synthetized 
and subjected to clinical studies by different research groups and pharmaceutical companies. 
Among these semisynthetic derivatives, Obeticholic acid (OCA) received in 2017 accelerated 
approval by the FDA for the treatment of Primary Biliary Cirrhosis (PBC) and is currently under 
advanced investigation for its use toward other hepatic pathologies, such as Non-Alcoholic 
Steatohepatitis (NASH). Considering the poor data available on OCA metabolism in impaired liver 
conditions, an in vivo assessment of OCA biodistribution in a model of cirrhosis should be 
mandatory for a total safety profile definition. 
This chapter deals with the development and validation of an HPLC-ESI-MS/MS method for the 
analysis of OCA, its metabolites and endogenous BAs in different biological fluids and organs. This 
method has been successively applied for the determination of OCA metabolism and 
biodistribution in an induced liver cirrhosis rat model. 
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2.1 Introduction 
2.1.1 Natural bile acids  
Bile acids (BAs) are endogenous acidic steroids synthetized in the liver from cholesterol, 
representing the main metabolites and the main excretion pathway from the body. Bile acids are 
involved in a series of physiological functions, such as the dissolution and transport of lipids 
through the formation of mixed micelles, the stimulation of biliary flow and the complexation of 
cations, such as Fe2+ and Ca2+, in order to promote their intestinal absorption [48]. 
Starting from cholesterol, the primary BAs, cholic acid (CA) and chenodeoxycholic (CDCA), are 
synthetized in the liver via cytochrome P450-mediated oxidation in a multi-step process [49]. Then, 
primary BAs are converted to the secondary BAs in the intestine by action of the intestinal 
microflora. Specifically, deoxycholic acid (DCA) and litocholic acid (LCA) are synthetized, 
respectively, from CA and CDCA through a 7-dehydroxylation reaction. Another secondary BA, 
ursodeoxycholic acid (UDCA) is produced in the intestine by the action of bacteria able to cause 
the epimerization of the hydroxyl group in position 7 of CDCA from  to  position [49]. Both 
primary and secondary BAs are subjected in the liver to phase II metabolism by the conjugation 
reaction with glycine, taurine, glucuronic acid and sulphuric acid (Figure 15).  Bile acids, despite 
the high number occurring within different species, share a common structure composed of a 
steroid backbone with four rings (conventionally labelled as A, B, C and D), a five-carbon sidechain 
terminating in a carboxylic acid, and different hydroxyl groups, whose orientation and position is 
variable and specific to each BA [49]. Bile acids present the typical chair conformation, which is 
due to the cis junction between the A and B rings; in some vertebrates, this junction is in trans 
position and for this reason they are called Allo-BAs. In the chair conformation, it is possible to 
define a concave side and a convex side. Hydroxyl groups and carboxylic groups are oriented 
toward the concave side, making it hydrophilic, while methyl groups are oriented toward the 
convex side, which is then hydrophobic. Hydroxyl groups, according to the specific BA and the 
species, can be either  (normally indicated with a solid line) or  (indicated with a dashed one) 
oriented. For example, human BAs present hydroxyl groups in positions 3, 7/ and 12, while 
in murine species the hydroxyl group can be found in position 6, but never in 12. 
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Figure 15. Principal BAs in human 
Bile acid synthesis follows two different metabolic pathways [50]: the classic neutral (mainly in the 
hepatocytes) and the alternative acidic one, which takes place in the liver and macrophages 
(Figure 16). The first pathway is the most important and it leads to the production of CA and CDCA, 
while the second one has a minor role and produces only CDCA. In the main route, the first step is 
the reaction catalyzed by the cholesterol 7α-hydroxylase (CYP7A1), consisting on the addition of 
the 7α-hydroxyl group to the cholesterol moiety. This reaction is very important because is the 
rate determining step of the entire biosynthesis process and is then involved in the regulation of 
BA levels in the body.  
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7α-HO-4-cholesten-3-one
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(CDCA)
Cholesterol
3b-HO-5-cholestenoic acid
CYP27A1
3b,7α-(HO)2-5-cholestenoic acid
CYP7B1
α-muCA
b-muCA
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Figure 16. Biosynthesis of BAs 
2.1.2 Enterohepatic circulation of BAs 
Following the consumption of lipids by diet, the duodenum cells secrete cholecystokinin in the 
circle. The subsequent binding of this hormone to the smooth muscle cells of the gallbladder wall 
promotes contraction. This results in the pulsatile secretion of bile (containing high concentrations 
of BAs) in the duodenum [51]. 
Under physiological conditions, the body BA pool is constant and is about 3-5 g; this homeostasis 
is made possible by two processes: BA reabsorption at intestinal level and their de novo synthesis 
from cholesterol. Up to 95% of the secreted BAs are reabsorbed at the intestinal level, not 
together with the products of lipid digestion, but through a defined enterohepatic circulation 
process [51]. 
The enterohepatic circulation is an extremely efficient recovery system, which seems to occur at 
least twice per meal, involving the liver, biliary tree, duodenum, colon and portal circle by which 
the reabsorbed molecules return to the liver. This recirculation is made necessary by the fact that 
the ability of hepatocytes to produce BAs is limited and insufficient to satisfy intestinal 
physiological needs if they were lost in high quantities. 
Most BAs are reabsorbed in the distal ileum, the lowest part of the small intestine, by means of a 
sodium-dependent transporter present in the enterocytes, called Apical sodium-dependent Bile 
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Acid Transporter (ASBT) [52], which carries out a transport of two sodium ions and a molecule of 
BA. 
Once inside the enterocyte, BAs are transported by the intervention of the Ileal Bile Acid-Binding 
Protein (IBABP) through the cytosol to the basolateral membrane, which is crossed thanks to the 
action of the Organic Solute Transporter alpha and beta (OST/OST) [53]. Through the portal 
circle, carried by albumin, they finally reach the liver, where their uptake from the circle is very 
efficient, so that from 50 to 90% are removed at the first step. Conjugated BAs are largely 
extracted by an active sodium-dependent transport mechanism, using the Na+-dependent 
taurocholate co-transport polypeptide (NTCP) [54]. However, sodium-independent transport may 
also take place by proteins from the family of Organic Anion Transporting Polypeptides (OATP), 
mainly OATP1B1 and OATP1B3 isoforms. 
In the enterohepatic circulation, the limiting passage is represented by the secretion of BAs in the 
biliary canal, largely due to the Bile Salt export pump (BSEP) [54] in an ATP-dependent process. 
This pump transports anionic BAs, which are the majority. Dianionic bile acids, like the conjugates 
with glucuronic and sulphuric acids, are secreted by different transporters such as MRP2 and 
BCRP. The unconjugated BAs are too lipophilic for being secreted as such, therefore they require 
conjugation with glycine and taurine, in order to increase the hydrophilicity. Indeed, in humans, 
before being secreted in bile, free BAs are conjugated almost entirely (up to 98%) with the amino 
acids glycine or taurine, to give respectively glycoconiugated and tauroconiugated BAs [55]. In 
particular, about 75% of CA and CDCA are conjugated with glycine, giving glycocholic acid (GCA) 
and glycochenodeoxycholic acid (GCDCA), while the remaining 25% with taurine to give 
taurocholic acid (TCA) and taurochenodeoxycholic acid (TCDCA). The conjugation process also has 
the effect to reduce the toxicity of the starting compounds. 
Once secreted into bile, BAs reach the ileum and then, if not reabsorbed, they enter the colon 
where a series of reactions accomplished by intestinal microflora lead to some structural 
modifications [56]. In particular: 
• Deconjugation of the conjugated BA lateral chain to produce free BAs plus glycine or 
taurine. This reaction is catalyzed by bacterial Bile Salt Hydrolase (BSH). 
• 7-dehydroxylation reaction on primary BAs to produce secondary BAs. This reaction is 
catalyzed by the enzyme 7-hydrolase and takes place only on unconjugated BAs, then 
preliminary deconjugation is a mandatory requisite. 
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• Oxidation and epimerization reactions on hydroxyl groups involve bacterial Hydroxysterol 
Dehydrogenase enzymes and, although it can occur at all positions, the most important is 
the reaction at position 7. The most prominent example is the conversion of CDCA to UDCA.   
Part of the secondary BAs produced in the colon are passively reabsorbed, while the unabsorbed 
fraction is lost through feces. It is important to underline that the formation of more lipophilic 
compounds in the colon area, although might appear uncommon, occur in order to enhance the 
reabsorption of BAs throughout the colonic mucosa and maintain constant the physiological BA 
pool. The reabsorbed secondary BAs, in analogy to their primary precursors, are taken up by the 
liver, conjugated and secreted into bile, being furtherly involved in the enterohepatic circulation. 
2.1.3 Receptorial activity of BAs  
Bile acids have been known for several physiological functions: 
• They are physiological surfactants able to promote the dissolution and the transport of 
lipids derived from diet. Indeed, thanks to the formation of micelles, BAs tend to include 
idrophobic substances with consequent formation of lipid emulsions with increased 
dispersion in the water mean. 
• At pancreatic level, they stimulate the secretion of digestive enzymes and cholecystokinin 
• They have a powerful antimicrobial activity in the intestine, especially DCA 
• They are able to regulate the biliary flow by osmotic mechanism  
Despite all these function, the presence of such a complex metabolism and fine regulation of their 
physiological concentrations have not been always clear and fully understood. The breakthrough 
point in the comprehension of BA physiological role was the discovery of their activity as 
endogenous ligands for two receptors: the Farnesoid X receptor (FXR) [57] and G protein-coupled 
receptor TGR5 [58]. 
The FXR is a nuclear receptor, mainly expressed in the liver and small intestine, which is involved 
in the regulation of BA synthesis by a negative feedback mechanism. At intestinal level, the 
activation of this receptor increases the expression of IBABP and basolateral OST/. Additionally, 
it increases the expression of fibroblast growth factor 15/19 (FGF15/19), which reaches the liver 
and suppresses the formation of BAs from cholesterol by inhibition of CYP7A1, limiting step of the 
entire biosynthesis, conjugation and transport of BAs [57]. At the same time, FXR regulates the 
processes of conjugation in the liver and, through the induction of the canalicular bile acid 
transport protein (ABCB11) and phospholipidfloppase (ABCB4), is able to limit and control BA 
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cytotoxicity in the intestinal tract [59]. Totally, FXR plays a major role in the cross-talk between 
liver and gut, limiting both BA synthesis and their toxic effects on hepatocytes or enterocytes. On 
these basis, FXR proved to be a very important target in clinical practice, considering its relevance 
in several liver and biliary tract diseases, such as cholestasis, gallbladder stones, hepatic 
inflammation, inflammatory bowel disease, cirrhosis and non-alcoholic steatohepatitis [59].   
The membrane receptor TGR5, on the other hand, is widely distributed, including endocrine 
glands, adipocytes, muscles, immune organs, spinal cord, and the enteric nervous system. The 
effect of TGR5 activation depends on the tissue where it is expressed and the signaling cascade 
that it induces. Generally, its activation plays a role in the control of glucagone-like peptide 1 (GLP-
1) secretion, which regulates pancreatic functions and sugar levels in blood [58]. Therefore, its role 
in regulation of basal metabolism and energy expenditure is well known and, consequently, is now 
recognized as a potential target for the treatment of metabolic disorders, such as type 2 diabetes 
and obesity [60].  
2.1.4 Semisynthetic analogues of BAs 
It has been showed that, among all endogenous BAs, CDCA and CA are the most potent ligands 
towards FXR and TGR5, respectively [61]. 
On these basis, in recent years several efforts have been focused on the synthesis of semisynthetic 
analogues of CA and CDCA, with the goal to discover new lead candidates characterized by a more 
potent and selective activity towards FXR and TGR5 [62, 63]. This is due to the increasing 
awareness that both FXR and TGR5 are involved in several gastrointestinal and hepatic diseases 
and consecutively, the demand for new drugs able to target these receptors is increasing. The two 
receptors present small differences in the structure of the binding site, therefore it is possible to 
develop BA analogues with specific selectivity toward only one target or either able to ligate both, 
opening new leads for the simultaneous treatment of cholestatic liver diseases and metabolic 
disorders. 
It has been reported that small amendments in the structure of natural BAs can deeply modify the 
biological properties and for this reason the structure-activity relationship for what concerns the 
selective interactions with FXR and TGR5 have been studied in detail [62, 64].   
A prominent example is given by three semisynthetic analogues which are property of Intercept 
Pharmateuticals: INT-747, INT-777 and INT-767; the first two compounds are, respectively, 
activators of FXR and TGR5, while the third shows affinity for both. While INT-777 and INT-767 are 
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still in advanced clinical phase, INT-747 (also known as obethicolic acid or OCA) has been recently 
granted with the FDA approval for the treatment of primary biliary cirrhosis (PBC) and is currently 
sold under the commercial name of Ocaliva. 
2.1.5 Obeticholic acid in the treatment of PBC 
Primary biliary cirrhosis, also referred as primary biliary cholangitis, is a chronic autoimmune 
hepatic disease whose main features are the inflammation and the continue destruction of the 
hepatic biliary ducts [65]. These events lead to cholestasis, parenchymal injury due to BA excess, 
and eventually end-stage liver disease. The etiology of PBC has not been fully elucidated yet and 
no clear cause agents have been identified so far [66]. Recurring symptoms, observed in over 20% 
of patients with diagnosed disease are fatigue and pruritus [67]. Historically, the endogenous 
UDCA has been used as the only approved therapy for PBC, but only 40% of the treated patients 
has shown positive response to this compound [68]. Many other agents have been tested for the 
treatment of this degenerative disease, including colchicine [69], fibrates [70], and methotrexate 
[71]. However, these other therapies have not showed any effectiveness, thus a critical need for 
new pharmacotherapies to treat PBC and prolong survival from this disease is one of the most 
demanding issues nowadays. 
Obeticholic acid is a semisynthetic BA analogue obtained from CDCA through the addition of a 6-
ethyl group. This structural modification confers two main advantages in respect to its 
endogenous analogue: a 100-fold higher binding affinity toward FXR and higher resistance against 
the 7-dehydroxylation by intestinal bacteria, allowing an increased persistence within the 
enterohepatic circulation [62]. This compound is rapidly absorbed and efficiently conjugated to 
glycine and taurine and then undergo enterohepatic recirculation, similarly to CDCA. 
Pharmacokinetic profiles are also broadly similar, with the exception of the 7-dehydroxylation step 
being restricted to CDCA [72], as the steric hindrance provided by the ethyl group in position 6 
impairs this kind of reaction. OCA is a first-in-class agonist that selectively binds to the FXR, 
accomplishing the suppression of the hepatic BA production and increasing bile flow, thus leading 
to a reduced exposure of the liver to toxic levels of BAs [73]. These actions should clinically 
translate into decreased parenchymal liver injury caused by BAs, resulting in improved 
biochemical enzyme profiles and decreased disease progression of PBC. Thus, the novelty 
introduced by OCA is based on its capability to bind FXR with high selectivity and potency (EC50 
0.09 M vs 8.6 M of CDCA), which is totally different mechanism in respect to UDCA (no activity 
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toward FXR), whose therapeutic efficacy was only based on the displacement of more detergent 
BAs in the human pool. OCA has been successfully evaluated in clinical studies in PBC patients 
[74]. In addition, OCA enhances insulin sensitivity in patients with NAFLD and type 2 diabetes [75] 
and reduces liver fibrosis in NASH patients [76]. OCA has recently been granted accelerated 
approval by the U.S. Food and Drug Administration for the treatment of PBC and is commercially 
available as OCALIVA® (Intercept Pharmaceuticals, Inc.). 
The encouraging results from Phase II and III studies represent a significant milestone in PBC; 
however, longer term efficacy of OCA and the general applicability to the entire PBC population is 
still to be confirmed in prospective follow-up studies. This is of particular importance given the 
limited number of patients enrolled in this kind of clinical trials, which is a symptom of the relative 
infrequency of PBC globally [77].  
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2.2 Aim and rationale 
The liver has a network of nuclear receptor-regulated pathways that coordinate the synthesis, 
hepatic uptake and transport of BAs, modulating their concentrations in the liver. The most 
relevant nuclear receptor is FXR, which is agonistically controlled by BAs and which regulates a 
variety of target genes involved in controlling BAs, lipids, glucose, inflammation, and fibrosis. 
FXR activation inhibits BA synthesis and protects against the toxic hepatic accumulation of BAs by 
regulating most of the BA hepatic transport proteins and promoting detoxification from the liver 
through phase I and phase II metabolism. These mechanisms make FXR agonists a target for 
treating cholestatic liver diseases, as PBC, PSC and NASH. 
OCA is a 6α-ethyl derivative of CDCA, the natural FXR agonist in humans. OCA is a first-in-class 
selective FXR agonist, originally described for its anti-cholestatic and hepatoprotective properties. 
OCA has been successfully applied in the treatment of PBC and has received accelerated approval 
from FDA. Additionally, it is under clinical evaluation for the treatment of other hepatic diseases, 
such as NAFLD and NASH. 
In healthy rats, OCA is metabolized in a similar manner to the structurally related CDCA but is 
more metabolically stable in terms of intestinal bacterial 7α-dehydroxylation. Unfortunately, poor 
data are available on OCA metabolic profile and biodistribution in conditions of severe liver 
impairment. Indeed, the increased plasma concentration of BAs in liver disease is due to deficient 
liver uptake, impaired metabolism, defective bile secretion, dysbiosis in the gut microbiota, and a 
portosystemic shunt between the portal vascular system and systemic circulation. It is thus 
important to evaluate whether, due to its high lipophilicity, OCA occurs at high hepatic and serum 
levels in end-stage liver disease. Besides, it is essential to assess OCA metabolic profile in 
conditions of hepatic failure to determine if any uncommon and potentially toxic metabolites are 
formed to facilitate its excretion. 
Given that OCA is used to treat PBC, and considering the above safety issue, this chapter deals 
with the metabolism and biodistribution of OCA and endogenous BAs after a single oral dose (30 
mg/kg) in rats with CCl4-induced decompensated cirrhosis. With this aim, an HPLC-ES-MS/MS 
method was developed and validated to quantify endogenous BAs, OCA and its main metabolites 
in rat plasma, liver, stools, small intestine content, colon content, urine and kidney samples. The 
targeted endogenous BAs were only free BAs and their relative taurine conjugates, as glycine 
conjugates do not occur in rat. As regards OCA metabolism, a series of possible metabolites were 
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assumed on the basis of the typical metabolic pathways involving BAs. The method was tailored in 
order to cope with different analytical challenges, such as: 
• Sensitivity issues related to the presence of very low concentrations in biological samples. 
• Selectivity issues related to the necessity to discriminate structurally similar compounds 
(isomers, epimers, etc…). 
• Suitable and efficient clean-up procedures from the very complex biological matrices 
investigated. 
• Identification of unknown or uncommon hepatic metabolites potentially occurring in case 
of liver impairment conditions.  
The metabolism and biliary secretion of OCA in a bile fistula model in cirrhotic rats in the three 
hours following intravenous infusion of OCA has been reported as well. This kind of experiment 
allowed the evaluation of BA net hepatic uptake, biotransformation, and secretion during cirrhosis 
progression. 
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2.3 Materials and methods 
2.3.1  Chemicals 
Endogenous BA analytical standards (CA, CDCA, DCA, LCA, UDCA, and their taurine conjugates) 
were purchased from Sigma-Aldrich (Saint Louis, USA). Standards of OCA, its taurine conjugate (T-
OCA) and glycine conjugate (G-OCA) were kindly provided by prof. Roberto Pellicciari (University 
of Perugia, Italy). Isopropanol (iPrOH), MeOH and ACN (HPLC-grade, Lichrosolv®) were purchased 
from Merck (Darmstadt, Germany). Acetic acid (98% purity) and ammonium hydroxide (98% 
purity) were purchased from Fluka (Buchs, Switzerland). Water of HPLC-MS grade (Millipore) was 
produced using the depurative system Milli-Q Synthesis A 10 (Molsheim, France). Other solvents 
were all of analytical grade. 
Stock standard solutions of all the BA standards were prepared in MeOH at concentration of 1 
mM. These stock solutions were aliquoted and stored at -20 °C to minimize potential solvent 
evaporation. Mixed WSs containing all compounds were made by appropriate dilution of the stock 
solutions in MeOH in the range 0.1–100 M and stored at 4 °C. Calibration solutions in the range 
0.01–10 M were prepared before the analysis by 1:10 dilution of the WSs in mobile phase, which 
was a mixture of H2O-MeOH-ACN (35:15:50). The QCs containing all the analytes were obtained at 
concentrations 0.2 μM, 1.0 μM and 5.0 μM. These samples were used for the method validation or 
injected randomly during the analysis in order to control the normal behavior of the analytical 
system. 
1.3.2  Instrumentation 
The chromatographic apparatus consisted of a Waters Alliance 2690 Chromatograph (Milford, MA, 
USA) with 120 position autosampler and thermostat coupled with a mass spectrometer triple 
quadrupole and electrospray interface (QUATTRO LC, Waters). The column was a WATERS X-select 
CSHTM Phenyl-Hexyl 5.0 m (2.1 mm × 150 mm). 
1.3.3  HPLC-ESI-MS/MS conditions 
Chromatographic separation was achieved using a reversed phase Phenyl-Hexyl column. The 
mobile phase was constituted by HPLC grade water with 15 mM ammonium acetate at pH 8.00 (A 
component) and ACN-MeOH (75:25) (B component). Different LC gradients were evaluated during 
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the method optimization. The best separation was obtained with the following gradient of the B 
component: 10 min 35%, 11 min at 45%, 4 min at 90%, 10 min at 35%, (total run time 35 min) at 
0.15 mL/min flow rate. Each variation in the eluent composition was instantaneous. The column 
was maintained at 45 °C and the injected sample volume was 5 L. The TIC with all the analytes is 
reported in Figure 17.  
 
 
Figure 17. Total ion current chromatogram reporting the HPLC separation on a Phenyl-
Hexyl column of endogenous BAs, OCA, T-OCA and G-OCA. The elution order is: TUDCA 
(1), UDCA (2), TCA (3), CA (4), TCDCA (5), CDCA (6), TDCA (7), DCA (8), G -OCA (9), TLCA 
(10), T-OCA (11), LCA (12), OCA (13) 
The column effluent was introduced into the ESI source, operating in negative ion, connected to a 
triple quadrupole mass spectrometer operating in MRM mode. The experimental MS conditions 
were properly tuned by direct infusion of each compound (1 M of each analyte; 2 mL/h infusion 
rate). Capiilary voltage was set at -2.7 KV, cone at 60 V (unconjugated BAs) or 90 V (conjugated 
BAs), source and desolvation temperature were respectively set at 130 °C and 200 °C, while the 
collision gas was argon. The two most abundant signals in extracted ion chromatogram (EIC) were 
monitored for each compound. The most intense was used for the quantification, the second one 
for the compound confirmation. Specifically, for unconjugated BAs, only the transition [M - H]- > 
[M - H]- was used, while for conjugated BAs the transition [M - H]- > [M - H]- was used for the 
quantification and the transitions [M - H]- > taurine fragment (m/z 124.4) or [M - H]- > glycine 
fragment (m/z 74.3) were used for the confirmation. In Table 6 were reported the retention times 
and the MS/MS transitions used for the identification and quantification of each compound. 
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Table 6. Retention times and MS/MS transitions for all the analyzed BAs 
BA Retention time (min) Transition (m1/z1 > m2/z2) 
CA 8.3 407.4 > 407.4 
CDCA 14.3 391.4 > 391.4 
DCA 17.8 391.4 > 391.4 
UDCA 6.2 391.4 > 391.4 
LCA 23.3 375.4 > 375.4 
TCA 7.4 
514.4 > 514.4 (quantification) 
514.4 > 124.4 (confirmation) 
TCDCA 13.1 
498.4 > 498.4 (quantification) 
498.4 > 124.4 (confirmation) 
TDCA 17.8 
498.4 > 498.4 (quantification) 
498.4 > 124.4 (confirmation) 
TUDCA 5.3 
498.4 > 498.4 (quantification) 
498.4 > 124.4 (confirmation) 
TLCA 22.1 
482.4 > 482.4 (quantification) 
482.4 > 124.4 (confirmation) 
OCA 24.7 419.4 > 419.4 
T-OCA 22.8 
526.4 > 526.4 (quantification) 
526.4 > 124.4 (confirmation) 
G-OCA 20.9 
476.4 > 476.4 (quantification) 
476.4 > 74.3 (confirmation) 
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2.3.4 Sample preparation 
2.3.4.1 Bile samples 
Rat bile samples were thawed and diluted 1:100 or 1:10 (v/v) with mobile phase. The final solution 
was filtered, transferred to an autosampler vial and 5 μL were injected into the HPLC-ESI-MS/MS 
system. 
2.3.4.2 Plasma and urine samples 
Plasma (100 µL) or urine (200 µL) samples were diluted 1:6 (v/v) with 0.1 M NaOH and heated to 
64°C for 30 minutes. This solution was subjected to solid phase extraction (SPE) procedure using 
C18 cartridges. The SPE cartridge was conditioned with 5 mL of MeOH and 5 mL of water prior to 
sample loading. Plasma samples were loaded into the conditioned cartridge and then washed with 
10 mL of water. The cartridge was then eluted with 5 mL of MeOH. The eluate was dried under 
vacuum and then reconstituted with 100 µL of the mobile phase, filtered, transferred to an 
autosampler vial and 5 µL were injected into the HPLC-ES-MS/MS instrument. 
2.3.4.3 Liver and kidney samples 
Aliquots weighing approximately 0.5 g were taken from different points of the sample. These 
aliquots were weighted and 2 mL of phosphate buffer (0.005 M, pH 7.2) was added. The mixture 
was homogenized using a potter, which was then washed with 3 mL of MeOH. The mixture was 
subjected to sonication bath for 5 minutes, heated to 37 °C for 20 minutes, and centrifuged at 
2100 rpm for 15 minutes. One milliliter of the supernatant dried under vacuum and the resulting 
residue then suspended with 2 mL of sodium hydroxide (0.1 N). The resulting solution was 
sonicated for 10 minutes, heated to 64°C for 30 minutes and SPE clean-up was carried out on C18 
extraction cartridges as described above. The eluate was dried under vacuum, reconstituted with 
100 µL of the mobile phase, filtered, transferred to an autosampler vial and 5 µL injected into the 
HPLC-ES-MS system. 
2.3.4.4 Feces and intestinal content samples 
Feces or intestinal content sample was collected and homogenized using a mixer. Aliquots 
weighing approximately 1 g were taken from the homogenate. Each aliquot was weighed and 3 mL 
of iPrOH were added. The mixture was left under stirring overnight and then centrifuged at 2100 
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rpm for 10 minutes. The supernatant was then diluted 1:10 (v/v) with mobile phase, filtered, 
transferred to an autosampler vial and 5 µL injected into the HPLC-ES-MS system. 
2.3.5  Method validation 
Method validation was performed according to ICH guidelines. Selectivity, LOD, LOQ, calibration 
range, precision, accuracy and matrix effect were evaluated for each analyte in all the studied 
matrices according to the protocols reported in paragraph 1.3.4. The matrix effect in each 
biological matrix was calculated at three concentration levels as the ratio of the analyte in mobile 
phase with respect to the analyte in the real sample fortified at the end of the clean-up. The 
recovery after SPE was calculated as percentage ratio of each analyte concentration at three 
concentration levels after and before SPE extraction. 
2.3.6  In vivo studies 
2.3.6.1 CCl4-induced rat model of cirrhosis 
All experiments were carried out according to the guidelines set forth by EEC Directive 86/609 on 
the care and use of experimental animals. The protocol for the induction of cirrhosis was approved 
by the Institutional Ethics Committee of the University of Bologna (Protocol CES 25. 57/80). All 
studies involving animals are reported in accordance with the ARRIVE guidelines [78]. 
Male Winstar-Han rats (Charles River Laboratories, Calco, LC, Italy), weighting 225-250 g, were 
housed for 3 weeks before the experiments, in order to achieve a complete adaptation in view of 
the following possibly harmful procedure. The induction of cirrhosis was preceded by one-week 
phenobarbital administration (0.3 g/L in drinking water), therefore at the beginning of the study (1 
month after the animal were housed), their weight was considerably increased. Cirrhosis was 
induced by carbon tetrachloride (CCl4) inhalation [79]. Phenobarbital administration was 
continued throughout the study as an enzyme inducer. Animals were housed in a controlled 
environment (22–24 °C), maintained on a standard 12 hours light/dark cycle and had free access 
to food and water throughout the study. The rats were placed in a gas chamber (70×25×30 cm) 
and compressed air, bubbling through a flask containing CCl4, was passed into the gas chamber via 
a flow meter (1 L/min). Animals were exposed to the gas atmosphere twice a week, starting with 
0.5 min of bubbling and 0.5 min in the gas atmosphere. Afterwards, the time was increased to 1 
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min and then by 1 min until 5 min of air flow and 5 min in gas atmosphere were reached. The 
mortality rate associated with this induction method was approximately 15%. 
Throughout the study, at weekly intervals, the animals were weighted and their conditions were 
monitored, including body weight changes, external physical appearance, behavioral and 
physiological changes (e.g., body temperature, hormonal fluctuations, and clinical pathology).  
In order to define a cirrhosis score for each animal, histological activity and fibrosis, biochemical, 
clinical encephalopathy and ascites scores were combined into overall scores. All animals used for 
this study had overall cirrhosis score between 10 and 30. 
2.3.6.2 Biodistribution of OCA and endogenous BAs 
Rats with decompensated cirrhosis were divided into 7 groups (3 rats each). Group 8 contained 
healthy control rats. Eight hours after food withdrawal, OCA suspended in 300 μL saline solution 
was administered by gavage at a single dose of 30 mg/kg. 
Groups 1, 2, 3, 4, 5, and 6 were sacrificed respectively at 1, 2, 4, 8, 24, and 48 h following OCA 
administration. OCA, its metabolites and endogenous BAs were measured in plasma, liver, kidneys, 
and the contents of small intestine and colon. 
Rats of groups 5 and 6 were kept in metabolic cages for 24 h and 48 h. In these two groups, OCA 
and its metabolites were also measured in urine and stools for complete mass balance and 
biodistribution evaluation. The cirrhotic rats of group 7 were placed in metabolic cages for 24 h 
without OCA administration. Group 8 comprised matched control healthy rats, receiving OCA with 
the same modalities. Globally, 21 cirrhotic rats and 18 healthy rats were used for the 
biodistribution study.  
At the sacrifice time, after anesthesia (20 mg/kg Zoletil), blood was withdrawn in heparinized 
tubes, centrifuged and plasma collected as supernatant. Additionally, liver, intestinal contents 
(small and large intestine), kidneys, stools, and urine were collected. All biological samples were 
immediately stored at -80 °C before the analysis. 
2.3.6.3 Intravenous infusion of OCA in the bile fistula rat model 
The study was performed on 12 rats: 3 healthy rats and 9 cirrhotic rats (3 rats/group) at 8, 10, and 
13 weeks following CCl4 administration. In anesthetized rats, the bile duct was cannulated and 
OCA was intravenously infused at a dose of 1 µmol/min/kg over 1 h [80]. Bile was collected every 
15 min for 3 h. The concentrations of endogenous BAs, OCA and its metabolites in bile were 
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measured. The bile flow was gravimetrically calculated and expressed as μL/min/kg, while the 
secretion rate was calculated from the bile volume and the BA concentration and expressed as 
μmol/min/kg. 
2.3.7 Quantification and statistical analysis 
A seven-point calibration curve in the range 0.05-10 M in mobile phase was used for the 
quantification of the different analytes within all the different biological matrices, except for 
plasma. For quantification in plasma, a calibration curve in BA serum free was used, by subjecting 
the single concentration points to the SPE clean-up described above. Considering that endogenous 
BAs naturally occur in plasma, this kind of matrix was preliminary subjected to a specific treatment 
[81] with catalytic carbon in order to get rid of the endogenous contribute and obtaining a blank 
serum. Linear calibration curves were obtained from the plot of the standard analyte peak area 
versus analyte concentration using a least-squares regression analysis. 
The quantitative data are presented as mean ± standard deviation (SD). A paired t-test was used 
to assess specific differences between cirrhotic and healthy rats in the different matrices analyzed. 
The comparisons between healthy and cirrhosis groups in a specific organ/fluid were performed 
considering the total OCA concentrations or recoveries, intended as the sum of OCA and the 
quantified metabolites, at the same time-points. The level of statistical significance was set at 
p<0.10. The choice of this value as cutoff can be considered reasonable when a small number of 
animals for each group is used and many biochemical data are collected. 
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2.4 Results and Discussion 
2.4.1 Mass spectrometry analysis of BAs 
Bile acids and their conjugates with taurine and glycine are acidic compounds and therefore are 
easily detected in negative ionization mode. The optimization of MS conditions has been carried 
out throughout the tuning of the electrospray ionization parameters: capillary and cone voltages, 
collision energy and source temperature. The proper tuning of these parameters allowed us to 
gain high current intensities for a sensitive detection of the compounds. In negative ionization 
mode, both free and conjugated BAs afforded the best signal intensities at low collision energies 
following the transition [M - H]- > [M - H]-, which was chosen for quantification purposes. For 
confirmation, possible fragmentation reactions, occurring at higher collision energies, were 
investigated. As depicted in Figure 18, free BAs did not afford any fragmentation, while taurine 
and glycine conjugates provided the ions having m/z 124.4 (taurine ion) and 74.3 (glycine ion), 
respectively. Consequently, the transitions [M - H]- > 124.4 and [M - H]- > 74.3 were selected, 
respectively, for the identification of taurine and glycine conjugates.  
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Figure 18. Tandem MS data of OCA (A), T-OCA (B) and G-OCA (c) precursor ions (m/z 
419.4, 526.4, 476.4, respectively) 
2.4.2  Method validation 
Calibration curve parameters for OCA, T-OCA, G-OCA and the endogenous BA quantification, in the 
range 0.05-10 g/mL, were obtained from the plot of the analyte standard peak area versus 
analyte concentration using a linear least-square regression analysis. Determination coefficients 
(r2) of the calibration curves were ≥ 0.995 for all analytes, both in mobile phase and plasma, 
meaning a good linearity over two orders of concentrations. 
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Limits of detection in mobile phase and plasma ranged from 2 ng/mL to 10 ng/mL, while limits of 
quantification in mobile phase and plasma from 5 ng/mL to 25 ng/mL for all the investigated 
analytes. 
Variation coefficients and bias% calculated, both intra- and inter-daily, were less than 5% for all 
analytes at the different concentration levels, indicating that the method possesses satisfying 
precision and accuracy, and then suitable for the purpose of the study. 
The comparison between standard solutions and fortified samples with known amounts of analyte 
and blank samples showed good selectivity in multiple reaction monitoring (MRM) mode, as no 
interfering signals, potentially able to affect the identification of the target analytes, were 
observed. 
Matrix effect percentage was evaluated at three concentration levels in all the studied matrices. 
Matrix effect values higher and lower than 0% indicated, respectively, ionic increase (positive 
matrix effect) or ionic suppression (negative matrix effect). In all the studied matrices, with the 
exception of plasma, matrix effect values were negligible, being always below 10% for all the 
studied analytes. In plasma, matrix effect higher than 20% was observed, leading to the necessity 
of calibration curves built in BA-free plasma. 
The efficiency of solid phase extraction during sample clean-up was calculated by Rec%. 
Experimental values were close to 100% for all the investigated analytes, indicating the efficacy of 
this process. The pre-analytical treatment of the different matrices was tailored in order to obtain 
a sensitive and selective quantification of the investigated BAs. For this reason, different SPE 
procedures have been tested throughout the screening of different eluents and stationary phases. 
The main advantages of the pre-analytical protocols that we have developed consist on the low 
matrix effects and the high recoveries at different concentration levels, and the possibility to 
concentrate the sample with consequent increase in the sensitivity of the detection. Additionally, 
with the exception of plasma, the possibility to use calibration curves in mobile phase allowed a 
fast and accurate quantification in all the analyzed matrices. 
2.4.3 Tentative in vivo metabolism of OCA 
In rat, natural BAs are preferentially conjugated with taurine and not with glycine, although this 
alternative cannot be excluded in general. Sometimes, it is also possible that hydroxylation of the 
sterol moiety occurs, in order to promote the secretion into bile. Furthermore, during intestinal 
transit, the unabsorbed fraction in the small intestine reach the terminal ileum and the colon 
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where BAs are metabolized by the intestinal bacteria. This involves dehydroxylation, oxidation and 
epimerization reactions, as these kinds of products have been observed in stools. In the liver and 
small intestine, conjugation with glucuronic or sulphuric acids at one or more hydroxyl groups 
occurs, leading to the formation of (di)glucuronides and (di)sulphates, in order to produce more 
hydrophilic compounds easily excreted through stools or urine. On these basis, it has been 
assumed that OCA might undergo similar metabolism and then all the possible expected 
metabolites have been investigated and tentatively identified according to the m/z values of the 
[M - H]- ion or possible fragmentation reactions. Since the standards necessary for their precise 
identification and quantification were not available, a semiquantitative analysis was performed for 
these compounds using the calibration curve of the most similar BA analogue. Figure 19 reports 
the structure of all the assumed OCA metabolites tentatively investigated for the assessment of 
OCA metabolism. 
 
Figure 19. Structures of all the assumed OCA metabolites  
2.4.4 Concentrations of OCA, its metabolites and endogenous BAs 
2.4.4.1 Plasma 
In cirrhosis, OCA and main metabolites concentrations were significantly higher than in controls: 
mean maximum levels (28.3±6.9 μmol/L) were reached 8 h after OCA administration (0.45 ± 0.07 
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μmol/L in controls) (p<0.01). In cirrhosis, OCA was initially unconjugated. It then decreased with 
formation of T-OCA and the monoglucuronide (Glu-OCA), as reported in Figure 20A. After 24 h, 
total OCA concentration was 5.1 ± 2.9 µmol/L, both free and taurine-conjugated. After 24 h, OCA 
concentration in controls was significantly lower, 0.27 ± 0.04 µmol/L (p<0.05), and mainly 
unconjugated (Figure 20B).  
Concentrations of endogenous BAs were higher than total OCA, in both cirrhotic and healthy rats. 
As a general trend, OCA and its metabolites concentrations of were higher in rats with high 
endogenous BAs. 
2.4.4.2 Liver 
At 24 h after administration, the mean hepatic total OCA concentration in cirrhotic rats was 
significantly higher (p<0.10) than in controls (1.21 ± 0.43 vs 0.56 ± 0.11 µmol/g, respectively), as 
shown in Figure 20C and 20D. The maximum hepatic concentration in cirrhosis was reached after 
24 h. However, it was still present after 48 h (0.47 ± 0.17 µmol/g), significantly higher than in 
controls (0.08 ± 0.02 µmol/g) (p<0.05). OCA was mostly conjugated with glycine (~50%) and to a 
lower extent with taurine (~30-40%). The maximum concentration of OCA in the liver of cirrhotic 
rats was about 2 times higher than in controls. However, the total hepatic concentration of 
endogenous BA was at least 100 times (50-80 µmol/g) higher. In particular, liver concentration of 
endogenous BAs in cirrhotic rats was about 2 times higher than in healthy rats. This result is in 
agreement with Fischer [82], who showed that hepatic concentrations of bile acid in cirrhosis are 
about 1.8 times higher than in healthy subjects. 
2.4.4.3 Small intestine content 
At 1 h after administration, OCA was not present in the intestinal contents of either cirrhotic or 
control rats. It then increased progressively, reaching a maximum after 24 h (4.7 ± 2.4 in cirrhosis 
and 1.8 ± 0.7 µmol/g in controls), without significant differences (p NS) between the groups 
(Figure 20E and 20F). T-OCA was the predominant form, followed by free OCA, which increased 
progressively up to 8 h. In the small intestine, the maximum BA concentration was always higher 
than the OCA concentration in both cirrhotic and healthy rats. Endogenous BAs maintained similar 
values, while OCA decreased over time.  
2.4.4.4 Colon Content 
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In cirrhosis, OCA concentration in the colon increased over time, reaching a plateau after 24 h and 
decreasing at 48 h (0.55 ± 0.22 µmol/g and 0.37 ± 0.28 µmol/g, respectively), as shown in Figure 
20G. OCA concentration in cirrhotic rats was similar to controls (p NS) after both 24 h and 48 h 
(0.40 ± 0.10 µmol/g and 0.28 ± 0.06 µmol/g), as reported in Figure 20H. OCA was mostly present in 
unmodified form, because the unabsorbed conjugated form in the small intestine underwent 
bacterial deconjugation. Colon bacteria, on the other hand, are responsible for the formation of 3-
oxo-OCA, obtained from the oxidation of the hydroxyl group in position 3. Moreover, the 
endogenous BAs were still higher than OCA in both groups. 
2.4.4.5 Kidneys 
OCA, its main metabolites and endogenous BAs were present at very low concentrations in 
kidneys, at less than 0.001% of the administered dose in both cirrhotic and healthy rats (data not 
shown).  
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Figure 20: Concentrations (mean ± SD) of OCA, its metabolites, and endogenous BAs  in 
different organs and fluids of cirrhotic and healthy rats, at different time -points after a 
single oral administration of OCA (30 mg/kg) 
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2.4.5 Biodistribution of OCA, its metabolites and endogenous BAs in different 
organs 
The biodistribution of OCA and endogenous BAs in different organs was assessed at 24 h and 48 h 
after OCA administration (Table 7, Table 8, and Figure 21). We selected these time points because 
they can be reasonably considered the most relevant for a steady-state organs biodistribution. 
2.4.5.1 Plasma 
OCA and its metabolites reached higher concentrations in cirrhosis than controls. However, this 
represented only 0.3 ± 0.2% and 0.3 ± 0.3% of the recovered dose, at 24 h and 48 h respectively, 
showing a lack of major compartmentalization in peripheral blood (Figure 21). These values are 
higher (p<0.10) than controls (Table 7) and consistent with the different biodistribution of the 
endogenous BAs, as commonly observed in cholestasis. The total BA plasma concentration was 
significantly higher in cirrhotic rats than in controls (Table 8). Total BA concentrations were similar 
in cirrhosis treated with OCA and in untreated cirrhosis (p NS).  
2.4.5.2 Liver 
Cirrhotic and healthy rats showed differences in the biodistribution of OCA and its metabolites. At 
24 h after administration, there was no significant difference (p NS) in the recovered OCA doses 
between cirrhotic and healthy rats (40 ± 12% and 26 ± 8%, respectively). However, 48 h after 
administration, significant differences (p<0.01) were found (23 ± 7% in cirrhotic rats and 4 ± 2% in 
controls) (Figure 21). In cirrhotic rats, endogenous BAs were always higher than OCA with no 
significant difference at 24 h and 48 h after administration (p NS) (Table 8). 
2.4.5.3 Intestine 
There was no significant difference (p NS) between cirrhotic and controls rats in terms of OCA and 
metabolites recovery in small intestine and colon 24 h after administration. Here, they 
represented 48 ± 14% of the recovered dose in cirrhotic and 71 ± 20% in control rats (Figure 21). 
Similarly, 48 h after administration, comparable OCA amounts were recovered in intestinal 
contents of cirrhotic (37 ± 12%) and control rats (24 ± 6%) (p NS).    
2.4.5.4 Feces and urine 
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At 24 h after administration, total excretion of OCA in stools was relatively low in both cirrhotic 
and control rats (10 ± 3% and 3 ± 1% of the recovered dose, respectively) (Figure 21). This shows 
that OCA presents a relatively long biological half-life. At 24 h after administration, excretion of 
OCA in stools was significantly higher in cirrhotic rats than in controls (p<0.05). At 48 h, however, 
OCA was significantly lower in cirrhotic rats (40 ± 15%) than in controls (72 ± 17%, p<0.10). 
OCA urinary excretion was determined in cirrhotic rats only: the recovered dose at 24 h and 48 h 
after administration was 0.36 ± 0.17% and 0.08 ± 0.02%, respectively. In healthy rats, OCA 
concentration in urine was under the LOQ.  
At both 24 h and 48 h, faecal BAs were similarly present in unconjugated form in control and 
cirrhotic rats. No significant differences (p NS) in stool excretion were observed between cirrhotic 
and control rats (Table 8). There were higher urinary concentrations of free and tauro-conjugated 
BAs in cirrhotic rats than in control rats (p<0.10) (Table 8). 
Total OCA recoveries at 24 h and 48 h were 85 ± 12% and 98 ± 15% in cirrhotic rats, and 86 ± 14% 
and 87 ± 16% in controls (Table 7). This means that OCA was not metabolized into uncommon or 
unidentified compounds and was almost entirely recovered in the expected organs and fluids.  
In addition, 24 h and 48 h after administration of OCA, there were no differences in the 
distribution of BAs in the various tissues. The main differences were found between cirrhotic and 
heathy rats, but these differences were not influenced by administration of OCA. 
 
 
Figure 21. Percentage biodistribution (mean ± SD) of total OCA recovered at 24 h and 48 h after a 
single oral administration of OCA (30 mg/kg) in decompensated cirrhotic rats and healthy controls 
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Table 7. Percentage recovery of OCA and its main metabolites in the various organs and fluids 24 h 
and 48 h after administration (mean values ± SD) 
 
 
 
% RECOVERY AFTER 24 h (MEAN±SD) 
OCA T-OCA G-OCA Glu-OCA 3-oxo-OCA Total OCA P-value 
Plasma  
Cirrhosis 0.12±0.10 0.10±0.07 n.d. n.d. n.d. 0.22±0.15 
<0.10 
Healthy 0.01±0.01 n.d. n.d. n.d. n.d. 0.01±0.01 
Liver  
Cirrhosis 0.27±0.10 14±6 18±4 1.6±0.2 n.d. 34±9.8 
NS 
Healthy 0.20±0.10 9.0±3.8 12±4.3 1.3±0.5 n.d. 22±6.9 
Small int. 
Cirrhosis 4.8±3.9 28±7 0.43±0.33 0.10±0.09 n.d. 33±10.8 
NS 
Healthy 0.30±0.2 48±16 n.d. n.d. n.d. 48±16 
Colon  
Cirrhosis 6.8±1.4 0.06±0.03 0.10±0.04 n.d. 1.14±0.81 8.1±2.1 
NS 
Healthy 11±5.1 0.13±0.07 0.17±0.05 n.d. 1.6±0.05 13±5.2 
Kidneys  
Cirrhosis n.d. n.d. n.d. n.d. n.d. n.d. 
n.c. 
Healthy n.d. n.d. n.d. n.d. n.d. n.d. 
Feces  
Cirrhosis 8.7±2.6 n.d. n.d. n.d. 0.41±0.33 9.1±2.7 
<0.10 
Healthy 2.3±1.2 n.d. n.d. n.d. 0.13±0.11 2.3±1.2 
Urine  
Cirrhosis 0.03±0.03 0.01±0.01 0.01±0.01 0.29±0.21 n.d. 0.34±0.22 
<0.10 
Healthy n.d. n.d. n.d. n.d. n.d. n.d. 
 
% RECOVERY AFTER 48 h (MEAN±SD) 
OCA T-OCA G-OCA Glu-OCA 3-oxo-OCA Total OCA P-value 
Plasma  
Cirrhosis 0.12±0.10 0.14±0.10 n.d. n.d. n.d. 0.26±0.10 
<0.10 
Healthy 0.01±0.01 n.d. n.d. n.d. n.d. 0.01±0.01 
Liver  
Cirrhosis 0.25±0.15 8.2±2.6 13±4 1.4±0.07 n.d. 23±6.1 
<0.10 
Healthy 0.10±0.10 1.6±0.6 2.2±1.3 n.d. n.d. 3.9±1.8 
Small int.  
Cirrhosis 1.6±1.5 25±11 0.10±0.10 1.1±0.1 n.d. 28±12 
<0.10 
Healthy 3.0±1.2 8.9±2.1 n.d. 0.40±0.20 n.d. 12±3.0 
Colon  
Cirrhosis 6.8±1.4 0.07±0.01 0.15±0.10 n.d. 1.2±0.9 8.2±2.1 
NS 
Healthy 4.0±2.3 0.10±0.05 n.d. n.d. 1.3±0.9 5.4±1.9 
Kidneys  
Cirrhosis n.d. n.d. n.d. n.d. n.d. n.d. 
n.c. 
Healthy n.d. n.d. n.d. n.d. n.d. n.d. 
Feces  
Cirrhosis 38±17 n.d. n.d. n.d. 1.1±1.0 39.1±16 
<0.10 
Healthy 62±15 0.70±0.44 n.d. n.d. 2.7±1.2 65±14 
Urine  
Cirrhosis n.d. 0.04±0.02 0.03±0.02 n.d. n.d. 0.07±0.02 
<0.10 
Healthy n.d. n.d. n.d. n.d. n.d. n.d. 
n.d.= not detected 
n.c.= not calculated 
NS = not significant 
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Table 8. Concentration of free, taurine-conjugated, and total endogenous BAs 24 h and 48 h after 
OCA administration in cirrhotic and control rats, reported as µmol/L or µmol/g (mean values ± SD) 
 
Free endogenous BAs ± SD 
 
cirrhotic rats 
24 h 
healthy rats 
24 h 
p-value 
24 h 
cirrhotic rats 
48 h 
healthy rats 
48 h 
p-value 
48 h 
cirrhotic rats 24 h 
no OCA 
Plasma 12.6±7.1 0.9±0.5 <0.10 8.1±5.2 2.4±0.8 NS 17±15 
Liver 4.1±2.8 3.8±1.3 NS 6.1±2.6 3.9±1.8 NS 18±16 
Small int. 1.5±1.1 0.4±0.3 NS 1.2±0.4 4.4±1.4 <0.10 4.8±4.1 
Colon 1.9±1.1 1.3±0.6 NS 2.4±0.9 1.1±0.3 <0.10 0.55±0.32 
Feces 1.3±0.5 1.4±0.3 NS 4.8±2.1 1.5±0.7 <0.10 0.51±0.12 
Urine 3.4±1.4 0.17±0.08 <0.10 4.2±1.7 0.8±0.3 <0.10 4.2±3.6 
 
Taurine conj. endogenous BAs ± SD 
Plasma 5.3±4.2 1.8±1.1 NS 6.2±2.2 0.8±0.3 <0.10 10±5.3 
Liver 54±20 36±14 NS 66±27 26±7.6 <0.10 54±20 
Small int. 13.3±4.5 16±8.3 NS 8.9±3.3 6.8±2.6 NS 0.50±0.31 
Colon n.d. n.d. n.c. n.d. n.d. n.c. n.d. 
Feces n.d. n.d. n.c. n.d. n.d. n.c. n.d. 
Urine 1.8±1.1 0.07±0.03 <0.10 2.0±0.6 2.1±1.5 NS 1.4±1.1 
 
Total endogenous BAs ± SD 
Plasma 18±9.8 2.7±1.2 <0.10 14±6.1 3.2±0.7 <0.10 27±17 
Liver 58±17 40±12 NS 72±25 30±6.5 <0.10 72±30 
Small int. 14.8±3.6 16.4±7.2 NS 10.1±2.8 11.2±3.1 NS 5.3±4.1 
Colon 1.9±1.1 1.3±0.6 NS 2.4±0.9 1.1±0.3 <0.10 0.55±0.32 
Feces 1.3±0.5 1.4±0.3 NS 4.8±2.8 1.5±0.7 NS 0.51±0.12 
Urine 5.2±2.5 0.24±0.09 <0.10 6.2±2.2 2.9±1.5 <0.10 5.6±4.1 
n.d.= not detected 
n.c.= not calculated 
NS = not significant 
 
2.4.5.5 OCA and endogenous BA composition 
In both cirrhotic and control rats, T-OCA was the main OCA metabolite recovered in the different 
organs. Indeed, T-OCA was the predominant form in liver and small intestine content. Other minor 
metabolites were also formed, including the glycine conjugate (limited to the liver), the 3-
glucuronide (only in the liver and small intestine), and the 3-oxo metabolite (limited to the colon 
content and faeces). The possible mechanism for increased glycine conjugation in the liver is 
uncommon for the rat and is particularly interesting. Taurine conjugation depends on the balance 
of amino acids and the free taurine content in the liver. When OCA concentration exceeds taurine 
bioavailability, glycine conjugation occurs. After administration, the large amount of OCA reaching 
the liver is conjugated, firstly with taurine and then with glycine, in order to be secreted into bile. 
 64 
In the intestine, T-OCA and G-OCA are deconjugated by intestinal bacteria and OCA is passively 
reabsorbed. There is then less recycling of OCA to the liver, with taurine synthesis supporting its 
concentration in the liver. This affords a more efficient taurine conjugation over time. 
OCA is almost completely recovered (85% after 24 h, and 98% after 48 h), showing that it is not 
extensively converted to any uncommon or toxic metabolite and it does not remain in non-target 
tissues, with potential undesirable effects. Indeed, OCA reaches the hepatocytes via the portal 
vein by intestinal passive absorption, sharing hepatic uptake systems with BAs. This accounts for 
the similar pharmacokinetics, without any difference in metabolic pathways (except for the lack of 
7α-dehydroxylation), leading to higher conservation of the OCA pool. 
2.4.6 Hepatic metabolism and biliary secretion of OCA in the bile fistula rat model 
OCA was administered by intravenous infusion to cirrhotic rats (after 8, 10, and 13 weeks of CCl4 
inhalation). Using this model, the hepatic uptake, transport, and secretion of OCA into bile, 
independently of portosystemic shunt, have been evaluated. 
After 13 weeks of CCl4-induced liver damage, as reported in Figure 22, bile flow had significantly 
and progressively decreased from 60 ± 6 µL/min/kg (in healthy animals) to less than 20 ± 2 
µL/min/kg (p<0.01). 
 
Figure 22. Bile flow during femoral infusion of OCA at a dose of 1 μmol/min/kg for 1 hour in rats 
after 0 (control, Ctrl), 8, 10, and 13 weeks of CCl4 inhalation. Bile was collected every 15 min for 3 
h. The bile flow is expressed as μL/min/kg (mean ± SD). The gray area represents the normal range 
of bile flow variation 
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Similarly, between week 8 and week 13 of CCl4 exposure, biliary secretion of OCA (entirely as T-
OCA) progressively decreased. As reported in Figure 23, the maximum secretion rate of OCA in 
control rats decreased from 0.80 ± 0.10 µmol/min/kg, to 0.40 ± 0.05, 0.20 ± 0.03, and then to less 
than 0.05 ± 0.01 µmol/min/kg as cirrhosis progressed (p<0.01). Similarly, endogenous BA secretion 
decreased as cirrhosis progressed, as outlined in Figure 23, which reports the data for TCA and 
TmuCA, the most representative endogenous BAs of the bile composition. The hepatic clearance 
of OCA and endogenous BAs thus decreases as cirrhosis progresses. 
 
Figure 23. Secretion rates during femoral infusion of OCA at a dose of 1 μmol/min/kg for 1 h after 
0 (control, CTRL), 8, 10, and 13 weeks of CCl4 inhalation. Bile was collected every 15 min for 3 h. 
The secretion rate is expressed as μmol/min/kg (mean ± SD) 
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2.5 Conclusions 
Bile acids and their semisynthetic analogues are gaining much attention due to their potential 
therapeutic role in the treatment of cholestatic diseases. In this scenario, OCA covers an important 
role, being the first and only BA analogue currently approved for the treatment of PBC by virtue of 
its FXR activity. Unfortunately, its metabolism and biodistribution in conditions of severe liver 
disease have not been properly addressed, leading to several concerns about its safety profile. In 
this context, an HPLC–ESI-MS/MS method for the quantification of endogenous BAs, OCA and its 
main metabolites in rat plasma, liver, stools, small intestine content, colon content, urine and 
kidney samples. This method has been validated and successfully applied to an in vivo rat model of 
induced decompensated liver cirrhosis, in order to exclude the occurrence of any uncommon 
metabolism or bioaccumulation in specific organs. 
The results showed that, in decompensated cirrhosis, OCA metabolism and biodistribution in liver, 
plasma, and intestine are similar to endogenous BAs. There was no formation of unexpected 
phase 1 or 2 hepatic metabolites of OCA, suggesting lack of hepatotoxicity, even when OCA is 
present at higher liver concentrations compared to controls. OCA is efficiently conjugated with 
taurine and glycine and promptly secreted into bile. Therefore, after a single oral administration of 
30 mg/kg, OCA concentration in the liver reflects the altered biodistribution of BAs in 
decompensated cirrhosis, as recently reported [83]. OCA is always present at significantly lower 
concentrations than BAs, which are potentially much more cytotoxic. OCA is almost completely 
recovered (85% after 24 h, and 98% after 48 h), showing that it does not remain in non-target 
tissues, with potential undesirable effects. Two points have been clarified by results of the bile 
fistula rat experiments following intravenous infusion of OCA. Firstly, as liver damage increases, 
there is a progressive decrease in biliary flow and biliary secretion of OCA and BAs. This is 
independent of portal hypertension. This decrease can partially be explained by the altered 
hepatocellular and lobular localization of import and export proteins. Secondly, the biliary 
excretion for OCA and BAs becomes less effective with disease progression.  
In conclusion, OCA and endogenous BAs share a similar metabolism and biodistribution in both 
normal and liver disease conditions, although a single-dose administration of OCA did not alter the 
qualitative or quantitative compositions of BAs or their biliary secretion. The biliary secretion of 
BAs and OCA progressively decrease as liver damage and loss of hepatic architecture progress. 
However, it is worth to point out that OCA presents a longer residence time in the cirrhotic liver 
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compared to healthy rats, suggesting that clinicians should carefully consider the potential 
accumulation of OCA. 
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CHAPTER 3 
Target lipid determination in organic residue 
analysis 
There is an increasing amount of evidence showing that organic residue analysis (ORA), performed 
on material residing within archaeological finds, is able to address many historical questions about 
past diets, ancient practices, early use of natural substances, but also vessel production and 
related use. Ceramic materials represent an ideal environment for the survival of residual organic 
matter, as its absorption into the microporous structure prevents from long-term degradation. In 
fact, some investigations have shown that possible contamination arising from migration of soil 
components, or compositional alterations through microbial activity, are minimal for compounds 
absorbed in potsherds. Unfortunately, poor data have been reported so far about ORA studies 
conducted on cooking hearths, as it is thought that it is unlikely that any useful analytes have been 
surviving over the millennia within this kind of environment. However, this assumption has never 
been experimentally confirmed, leaving some uncertainty on this scenario. 
This chapter deals with the development of chromatographic/mass spectrometry based analytical 
methodologies to identify the organic pyrolysis products that reside within cooking hearths 
following the cooking of different foodstuffs. These protocols have been successfully applied for 
the analysis of residual organic materials present within archaeological finds, with the final aim to 
identify food/diet related chemicals whose qualitative and quantitative composition might 
represent biomarkers able to provide information related to past human activity.  
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3.1 Introduction 
3.1.1 Organic residue analysis 
The ability of our ancestors to fulfil their basic nutritional needs was a factor that shaped the 
evolution of modern man and the societies that followed. Therefore, the study of ancient dietary 
customs has been gaining much attention from historians and archaeologists. There is an 
increasing amount of evidence showing that organic residue analysis (ORA) is able to address 
many archaeological questions about past diets, ancient practices, early use of natural substances, 
but also vessel production and related use. Although many ORA applications target the 
identification of what food products were processed or stored in ancient vessels, it can also 
address wider questions regarding the ancient trade of goods and raw materials, ancient 
technologies, resource exploitation and acquisition, ritual practices, the domestication of plants 
and animals, and dietary reconstruction and subsistence practices. ORA has the potential to 
inform archaeological interpretations on scales ranging from a site context to local, national and 
global scale questions, together with the investigation of chronological change, again across small- 
to broad-scale contexts. 
Most of the organic residue analysis have been performed on absorbed material recovered from 
archaeological finds, like pots and vessels [84, 85]. Ceramic materials represent an ideal 
environment for the survival of residual organic matter because its absorption into the 
microporous structure prevents from long-term degradation. In fact, some investigations have 
shown that possible contamination arising from migration of soil components, or compositional 
alterations through microbial activity, are minimal for compounds absorbed in potsherds [86]. 
Hence, these residues are a direct reflection of the original contents and usage of ceramic vessels. 
It is always crucial to apply the analysis and subsequent interpretation of organic residues within 
the context of the archaeology and paleoecology of the settlement, region and period from which 
they derive. Organic residue information should be integrated with other lines of archaeological 
evidence, in order to provide the most meaningful answers to research questions. For example 
[87], in studies of animal product processing in prehistoric Britain, only a restricted range of 
ruminants need to be considered as likely sources of lipid extracted from vessels; these include 
cattle, sheep/goat and deer, with pig being the most common non-ruminant. In other regions or 
periods, the qualitative and quantitative composition of species might be different, guiding 
interpretations accordingly. 
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3.1.2 The Archaeological Biomarker concept 
The development of powerful analytical techniques, such as mass spectrometry, has allowed the 
study organic residues within archaeological material at molecular level. ORA can be used to 
accomplish the effective recovery and identification of biomolecules and related degradation 
products in archaeological materials, achieved through the application of the so-called 
Archaeological Biomarker concept [88]. This concept surrounds all the analytical methodologies 
developed for the analysis of organic archaeological finds at biomolecular level, with the aim to 
provide information related to past human activity. For example, pottery used in brewery can be 
distinguished from that used in cookery as each one harbors characteristic biomarkers [89]. 
Although the archaeological biomarkers refer to a variety of organic compounds, most of the ORA 
applications have been focusing on lipid profiling, as they are considered to be the most durable 
and greatly occurring in the archaeological residues [90]. Obviously, the application of this concept 
bears some natural issues, especially for what concerns the accomplishment of ORA 
investigations. Indeed, considering that all the residues encountered at the archaeological sites 
have biological origin, very complex mixtures normally occur. This complexity is furtherly 
worsened by some human activities, such as food preparation, and by the natural compositional 
alteration due to chemical and microbial decay during burial. 
The Archaeological Biomarker concept relies on matching the identified structures to molecules 
known to be present is organism or species likely exploited in the past [90] and sometimes the 
elucidation of a single component structure is sufficient to define the origin of an organic residue. 
For example [91], beeswax can be unequivocally identified by the highly specific aliphatic 
component pattern. Anyway, the assignment process of a biomarker to a specific organic source 
requires a high degree of rigor, as the consideration of other compounds in the residue might lead 
to the hypothesis of a putative source to be rejected. For example, a recent paper [92] reported 
the identification of beeswax in a residue on the basis of the presence of C23, C25, C27, C29, C31, and 
C33 n-alkanes; however, this assignment has been successively questioned considering that the GC 
profile of the sample was very similar to a petroleum mixture. On these basis, in case of 
occurrence of such ambiguities, firm conclusions on the nature of an organic residue must be 
drawn only in presence of stronger supporting evidences. 
Considering the complexity of the archaeological samples normally encountered in ORA studies 
and the often-occurring misleading interpretations, the correct identification of the biomarkers 
imperatively requires the use of advanced chromatographic and/or mass spectrometric 
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techniques. This is the reason for which the advances in this area have been greatly tied to 
analytical method improvements.            
3.1.3 The occurrence of organic residues 
Organic residues have the capacity to survive over considerable timescale within the 
archaeological site. They are often in association with several classes of artefacts, providing many 
insights on vessel use, site and regional economies/technologies. Organic residues can be 
recovered from ancient pottery as three main different forms: 
• Original content preserved within the pot as vessel filling. This is the rarest case, as only 
few examples have been reported so far [93]. 
• Residual matter looking as surface residue on the internal or external side of the vessel. 
Among these, carbonized residues, assumed to be the result of cooking failures, are the 
most common cases. These kinds of samples have been largely used for dating purposes 
[94]. External residues, on the other hand, are often associated to the fuel used for fire, 
applied decorations or materials used for reparation [95].  
• Residues absorbed in the walls of the pots, invisible to naked eye. This is the most common 
type of organic residue and it has revealed a wild series of biomarkers from an impressive 
range of commodities over several continents [96]. These include vegetable oils, terrestrial 
and marine animal fats, resins and plant waxes. These residues derive from the animal and 
plant products processing. 
Although the residues associated to potteries have been the most analyzed samples, many other 
archaeological finds keep arising great interest. Indeed, several reports have documented analysis 
performed on human and animal remains (like skeletal or tissue remains) [97], natural and fossil 
resins (especially materials used in ancient practice of decoration and restauration) [98], soils and 
sediments [99], and miscellaneous organic remains (like the bog butter hoards that constitute the 
largest deposits of organic residues ever reported in archaeology) [100].  
3.1.4 The stability of organic residues 
The ability of organic residues to survive within a hostile environment is still field of debate. 
Indeed, all organic compounds are potentially subjected to degradation, both chemical and 
biological. Consequently, there must be some kind of protection that allow the survival of certain 
molecular species. However, it is obvious that the structural differences between compounds 
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account for different preservation. Normally, more polar the substances are, then more likely to 
degrade they will be, especially if any essential elements are present. Following this criterion, the 
stability toward degradation of the different classes of compounds follows the order: lipids > 
carbohydrates ≈ lignin > protein > nucleotides; however, there are several factors able to affect 
this order somehow, according for example to the environment or to the history of an artefact 
[101]. 
Lipids are the most targeted compounds in ORA studies, as they represent the vast majority of 
occurring biomarkers within archaeological finds. This is mainly due to their hydrophobicity, which 
allows them not to be easily lost by leakage from the site of original deposition because of the 
percolation of underground water. Besides, their absorption on the substrate prevents from 
microbial degradation. However, it is noteworthy that even within a class of compounds, 
substantial differences might exist in the degradation paths of different sub-classes. For example 
[102], the decay of plant epicuticular waxes and animal fats co-deposited onto replica ceramic 
showed different patterns of decay. 
Mineral constituents of the pottery walls offer a protective environment in which organic 
molecules are partially shielded from microbiological degradation. It is presumed that this 
protective mechanism occurs through the enclosure of organic molecules within pore spaces 
inaccessible to exocellular enzymes produced by degrading microbes and protection through 
adsorption on substrate material surfaces [103]. Likewise, protection appears also to be conferred 
by entrapment within organic matrices, such as carbonized organic residues on pottery and 
aggregates of organic matter. 
Several environmental factors have been recognized to play a role in the organic residue 
preservation, including temperature, light exposure, degree of waterlogging, redox conditions and 
so on [96]. Desiccation is a very important parameter in this context, as it hampers the microbial 
growth and the consequent biodegradation. However, it does not prevent the extensive chemical 
oxidation of residues normally occurring over millennia. Nutrient limitation, especially of essential 
elements, may also limit the progress of degradation: once the concentrations of these elements 
get limited, the microbe activities will inevitably be slowed or even stopped. Although extremes of 
waterlogging and desiccation are unquestionably conducive to the survival of organic residues, 
alternating wetting and drying in climate zones where seasons of high rainfall are followed by hot 
dry periods appears to be detrimental to residue survival [96]. 
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 3.2 Aim and rationale 
Over the past three decades ORA studies have been performed on pottery from archaeological 
sites with great success. The detection of biomarkers indicative of specific foods has enabled 
researchers to develop an objective understanding of the diet consumed by ancient groups and 
cultures and allowed the possibility to trace the migration processes of ancient population across 
specific territories. Despite the achievements of potsherd analysis, the attempt of studying the 
dietary practices of individuals who lived prior to use of pottery has not been made with the same 
vigor. This lack of information about this kind of samples derives from a widespread and unverified 
assumption that biomarkers are highly unlikely to survive the destructive environment within a 
cooking hearth. 
The project was developed with the aim of exploring what kind of lipids might have been survived 
within hearth samples excavated from different archaeological sites. The analyzed samples, dating 
back 20000-50000 BCE, corresponded to an era when Neanderthals habited Western Europe. With 
this aim, different instrumental approaches and protocols have been developed and optimized to 
determine the optimal chromatographic and/or mass spectrometric condition to study a range of 
expected compound families. These include FAs, FAMEs, TAGs, sterols and steryl glucosides (SGs). 
Indeed, considering the age and the complexity of the samples, the choice of a target approach 
toward the most stable lipid classes that are recognized to be indicative diet-related biomarkers 
was preferred. Considering the necessity to investigate several lipid families, the selective 
ionization processes offered by different atmospheric pressure ionization techniques have been 
tested. Besides, shotgun analysis using ultrahigh resolution mass spectrometry methods have 
been compared with modern LC-MS approaches (RP-UHPLC-MS and UHPSFC-MS). 
The final aim of this project is to demonstrate that the study of hearth material in ORA has been 
critically undervalued and to provide the fundamentals for future investigations of new potential 
biomarkers in these kinds of samples.  
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3.3 Materials and methods 
3.3.1 Chemicals 
All the standards of FAs, FAMEs, TAGs, and sterols utilized in this study were of analytical grade. 
Capric acid (C10:0), valeric acid (C12:0), myristic acid (C14:0), palmitic acid (C16:0), stearic acid 
(C18:0) and arachidic acid (C20:0) standards were purchased from Sigma-Aldrich (Saint-Louis, US). 
Methyl decanoate (C10:0), methyl valerate (C12:0), methyl myristate (C14:0), methyl palmitate 
(C16:0), methyl stearate (C18:0), methyl oleate (C18:1), methyl linoleate (C18:2) and methyl 
linolenate (C18:3) were purchased from Sigma-Aldrich. β-sitosterol, stigmasterol, ergosterol and 
cholesterol were purchased from Sigma-Aldrich. Cholesteryl glucoside was purchased from Sigma-
Aldrich, while a mixture of SGs (β-sitosteryl glucoside, campesteryl glucoside, stigmasteryl 
glucoside, Δ5-avenasteryl and Δ7-avenasteryl glucoside) was purchased from Matreya Inc. Mixture 
of three purified triglycerides (16:0/14:0/14:0, 14:0/14:0/14:0 and 12:0/14:0/14:0) was kindly 
donated by Dr. Simon Gerrard (University of Southampton, UK). Methanol, EtOH, iPrOH, ACN, 
dichloromethane (DCM) and hexane (Hex), all of MS grade, were purchased from Fischer Scientific 
(Pittsburgh, US). Carbon dioxide (CO2) was >99% purity. Formic acid, ammonium acetate, 
ammonium hydroxide, sodium formate and other additives used were of analytical grade. 
Sterol and SG stock standard solutions were prepared, respectively, in iPrOH and DCM:MeOH (3:1) 
at a concentration of 1 mg/ml, while FA, FAME and TAG stock standard solutions, also at 
concentration of 1 mg/ml, were prepared in Hex. All the stock solutions were aliquoted and stored 
at -20 °C. Individual stock solutions were properly diluted in hexane to prepare standard 
calibration solutions containing different compounds in a concentration range of 0.01-10 µg/mL. 
These solutions were stored at 4 °C in order to avoid any potential variation in the nominal 
concentration.  
3.3.2 Instrumentation 
The UHPSFC-MS apparatus consisted of an ACQUITY UPC2 System with 96 positions autosampler 
and thermostat coupled with a single quadrupole mass spectrometer and API interface (Xevo XS-
SQ; Waters, US). The column utilized in this study were: HSS C18 1.8 μm particle size (3×100 mm), 
BEH 1.7 μm particle size (3×100 mm), BEH 2-EP 1.7 μm particle size (3×100 mm) and Torus 1-AA 
1.7 μm particle size (3×100 mm). 
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The UHPLC-MS apparatus consisted of an Ultimate 3000 System with 90 positions autosampler 
and thermostat coupled with a quadrupole-time of flight mass spectrometer and electrospray 
interface (Maxis; Bruker, US). The column utilized in this study was a HSS C18 1.8 μm particle size 
(3×50 mm). 
The FT-ICR MS system consisted of a solariX XR high-resolution mass spectrometer (Bruker, US).  
3.3.3 UHPSFC-MS analysis 
Different chromatographic columns and conditions have been tested in order to achieve the 
optimal separation of the different compounds. 
Final simultaneous separation of FAs, FAMEs and TAGs was achieved using a BEH 2-EP column. The 
selected mobile phase was CO2 (A component) and MeOH with 25 mM ammonium acetate (B 
component). The best separation was obtained at flow rate of 1.5 mL/min with the following 
gradient of the B component: 0 to 1 min at 0%, then linear increase to 1% in 1 minute and 
maintained for 1.5 minutes, then linear increase to 5% in 1 minute, then to 30% in another minute 
and maintained for 2.5 minutes (total run time 8 minutes). The column reconditioning time 
between each chromatographic run was 2 minutes.  
Final separation of sterols was achieved using a Torus 1-AA column. The selected mobile phase 
was CO2 (A component) and MeOH with 25 mM ammonium acetate (B component). The best 
separation was obtained at flow rate of 1.5 mL/min with the following gradient of the B 
component: 0 to 1.5 min at 0%, then linear increase to 5% in 0.5 minute and maintained for 1 
minute, then linear increase to 15% in 1.5 minute and maintained for 1 minute, then to 30% in 0.5 
minute and maintained for 2 minutes (total run time 8 minutes). The column reconditioning time 
between each chromatographic run was 2 minutes. 
In both separations, the column was maintained at 45 °C and the injected sample volume was 
2 μL. The total ion current chromatogram (TICC) reporting the complete separation of all the 
tested compounds is reported in Figure 24. 
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Figure 24. TICC reporting the separation of the tested FAs, FAMEs, TAGs using a BEH 2-EP column 
(A panel) and sterols (B panel) using a Torus 1-AA by UHPSFC-MS. The elution order for FAMEs is 
from C10:0 to C18:3; the elution order for TAGs is from 12:0/14:0/14:0 to 16:0/14:0/14:0; the 
elution order for FAs is from C10:0 to C20:0; the elution order for sterols is: cholesterol, β-
sitosterol, stigmasterol and ergosterol 
The column effluent was mixed with a make-up solvent, delivered by a secondary pump at a flow 
rate of 0.45 mL/min, and introduced into the API source, operating in negative or positive ion 
mode, connected to a single quadruple mass spectrometer operating in Full Scan mode or Single 
Ion Recording (SIM). ESI was selected as ionization interface for all the investigated lipid classes, 
except sterols, which were analyzed using an APCI interface. The use of a make-up solvent (sodium 
formate 20 µM in methanol for FAs, FAMEs, TAGs, and formic acid 1% in methanol for sterol 
analysis) was necessary in order to obtain a stable and reproducible spray and an ionization 
efficiency improvement. Table 9 reports the details regarding the detection of each compound. 
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In Table 10, the MS experimental conditions are reported, which were properly set up by single 
standard infusion. 
Table 9. Retention times, unique m/z and ion types obtained from the analysis of the different 
lipids by UHPSFC-MS 
Family Compound Retention time 
(min) 
Ion mass (m/z) Ion type 
FA 
Decanoic acid 4.64 ± 0.01 171.1 [M - H]- 
Valeric acid 4.78 ± 0.01 199.2 [M - H]- 
Myristic acid 4.88 ± 0.01 227.2 [M - H]- 
Palmitic acid 4.96 ± 0.01 255.3 [M - H]- 
Stearic acid 5.03 ± 0.01 283.3 [M - H]- 
Arachidic acid 5.10 ± 0.01 311.4 [M - H]- 
FAME 
Methyl decanoate 0.54 ± 0.01 209.3 [M + Na]+ 
Methyl valerate 0.58 ± 0.01 237.3 [M + Na]+ 
Methyl myristate 0.62 ± 0.01 265.4 [M + Na]+ 
Methyl palmitate 0.67 ± 0.01 293.4 [M + Na]+ 
Methyl stearate 0.72 ± 0.01 321.5 [M + Na]+ 
Methyl oleate 0.76 ± 0.01 319.5 [M + Na]+ 
Methyl linoleate 0.80 ± 0.01 317.5 [M + Na]+ 
Methyl linolenate 0.85 ± 0.01 315.5 [M + Na]+ 
TAG 
16:0/14:0/14:0 2.87 ± 0.01 773.8 [M + Na]+ 
14:0/14:0/14:0 2.95 ± 0.01 745.7 [M + Na]+ 
12:0/14:0/14:0 3.05 ± 0.01 717.6 [M + Na]+ 
Sterol 
Cholesterol 4.70 ± 0.01 369.5 [M + H - H2O]+ 
β-sitosterol 4.77 ± 0.01 397.5 [M + H - H2O]+ 
Stigmasterol 4.82 ± 0.01 395.5 [M + H - H2O]+ 
Ergosterol 4.97 ± 0.01 379.5 [M + H - H2O]+ 
 
Table 10. Mass spectrometry conditions for the different API techniques utilised during analysis by 
UHPSFC-MS 
Ionization mode ES- ES+ Ionization mode APCI+ 
Capillary voltage 
(KV) 
-2.7 +4.0 
Corona voltage 
(KV) 
+3.0 
Cone voltage 
 (V) 
+40 -25 
Cone voltage 
 (V) 
-30 
Source 
temperature (°C) 
150 150 
Source 
temperature (°C) 
150 
Desolvation 
temperature (°C) 
500 500 
Probe 
temperature (°C) 
400 
Desolvation gas 
flow (L/h) 
650 650 
Desolvation gas 
flow (L/h) 
550 
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 3.3.4 UHPLC-QTOF analysis 
Separation of FAs, FAMEs and TAGs was achieved using a C18 column. The selected mobile phase 
was water (A component) and MeOH (B component), both acidified with 0.2% of formic acid. 
The best separation was obtained at a flow rate of 0.5 mL/min with the following gradient of the B 
component: linear increase from 60 to 90% in 3.5 minutes, then 90% until 6.5 minutes, then linear 
increase to 100% in 0.5 minute and maintained for 6 minutes (total run time 13 min). The column 
reconditioning time between each chromatographic run was 2 minutes. 
The column was maintained at 40 °C and the injected sample volume was 2 μL. The TICC reporting 
the complete separation of all the tested compounds is reported in Figure 25. 
The column effluent was introduced into the ESI source, operating in negative or positive ion 
mode, connected to a quadrupole-time of flight mass spectrometer operating in Full Scan mode. 
In Table 11 the MS experimental conditions were reported, properly set up firstly by single 
standard infusion. 
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Figure 25. TICC reporting the UHPLC-ESI-QTOF separation of the tested FAs (A panel), FAMEs and 
TAGs (B panel), respectively in negative and positive ion scan, using a C18 column 
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Table 11. Mass spectrometry conditions for FAMEs, TAGs and FAs analysis by UHPLC-QTOF. The 
detection of FAMEs and TAGs was performed in positive ion mode, while FAs in negative 
Ionization mode ES- ES+ 
End plate offset (V) -500  +500 
Capillary voltage (V) +4000  -4000 
Drying temperature (°C) 230 230 
Nebuliser (Bar) 2.0 2.0 
Drying gas (L/min) 6.0 6.0 
m/z range 150-1500 150-1500 
 
3.3.5 FT-ICR MS analysis 
FT-ICR mass spectrometer was not coupled to any chromatographic system, as the high resolution 
and high accuracy of this instrument allows to discriminate ions with very close m/z values. The 
use of this instrumentation was limited to the confirmation of compounds suspected to be present 
in the samples but for which the relative standards were not available. The samples were directly 
infused onto the ESI source and mass spectra acquired according to the instrumental conditions 
reported in Table 12. Instrument was calibrated using a 10 ng/mL sodium formate solution. The 
instrumental conditions were optimized using standard solutions of the different compounds.  
Table 12. FT-ICR MS ionization parameters. FAMEs and TAGs were detected in ES+, FAs in ES- 
Ionization mode ESI- ESI+ 
End plate offset (V) -500  +500 
Capillary voltage (V) +4000  -4000 
Drying temperature (°C) 180 180 
Nebuliser (Bar) 1.2 1.2 
Drying gas (L/h) 4.0 4.0 
m/z range 150-1500 150-1500 
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 3.3.6 Sample preparation 
Archaeological samples were extracted following a procedure developed and optimized by the 
research group of prof. George Attard (University of Southampton, UK). Briefly, the homogenized 
hearth-material was weighted into a cellulose thimble and then placed on the Soxhlet apparatus. 
The quantity of material extracted varied according to the mass of the archaeological sample. The 
still-pot was filled with the first extraction solvent (Hex, 150 mL) and brought to reflux (2 hours at 
97.5 °C). Subsequently, the extract was dried under vacuum and then reconstituted in Hex. The 
extraction procedure was repeated using a secondary extraction solvent (Tol:MeOH, 1:2, 150 mL). 
Again, the extract was dried under vacuum prior resuspension in Hex. These samples were 
centrifuged, filtered and stored at -20 °C before analysis. 
3.3.7 Method validation 
Method validation was performed according to ICH guidelines. Selectivity, LOD, LOQ, calibration 
range, precision and accuracy were evaluated for each analyte according to the protocols reported 
in paragraph 1.3.4. 
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3.4 Results and Discussion 
3.4.1 UHPSFC-MS method for the analysis of FAMEs, TAGs and FAs 
One of the aims of this work was to develop a chromatographic method able to quantitatively 
analyze different lipid classes likely present within real archaeological samples. Considering that 
the amount of sample available for the analysis might be very low, it would be desirable that the 
method was able to target as many lipid classes as possible within a single chromatographic run. 
The targeted lipid classes selected for this kind of study were FAMEs, TAGs and FAs because they 
can be reasonably found in the real sample extracts and cover a large polarity range. Preliminary 
experiments using standard solutions of the analytes were performed in order to select the proper 
separation conditions, based on the choice of chromatographic column, mobile phase modifier, 
make-up solvent, column temperature, backpressure and mobile phase flow rate. 
Considering the above issues, the column selection was of great importance for the acceptable 
separation of the studied compounds. In this study, four columns were screened, including Waters 
Acquity UPC2 BEH, BEH 2-EP, HSS C18 and Torus 1-AA. The column performances are reported in 
Figure 26, in which the separation is based mainly on the chain length and the unsaturation 
degree. The C18 column reveals to be the most suitable for separating compounds differing for 
the chain length, like saturated TAGs, FAs and FAMEs, but is ineffective for separation requiring 
selectivity towards unsaturation degree, like unsaturated FAME (and likely unsaturated FAs or 
TAGs). The Torus 1-AA column shows selectivity similar to C18 but is not able to separate TAG and 
FA classes. The BEH column exhibit chromatographic selectivity exactly opposite to C18, being very 
effective in the separation of FAMEs with different unsaturation but poorly suitable for the 
separation of the other compounds. The BEH 2-EP column, on the other hand, exhibit good 
selectivity in respect to both unsaturation degree and chain length, being the most effective for 
complete separation of all the tested compounds. In addition, BEH 2-EP column reveals to be very 
reliable in separating the different compounds within a specific lipid class but is also able to afford 
good separation between lipid classes through very mild variations in the mobile phase 
composition. For these reasons and considering the potential applicability and extendibility of the 
method to other lipid classes, the BEH 2-EP was the column of choice for our studies. 
FAs are natural compounds characterized by the presence of the carboxylic group and therefore 
easily detectable in ES negative ion mode. FAMEs and TAGs, on the other hand, are detected only 
in positive ionization mode as sodium adducts. For this reason, a SIR program constituted of three 
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different detection windows, operating in negative or positive mode, was set making possible the 
simultaneous analysis of all these lipid classes within a single chromatographic run. In addition, the 
SIR detection mode ensures high sensitivity and specificity, reducing the interferences and 
increasing the signal to noise ratio. 
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Figure 26. TICC reporting the UHPSFC separation of the tested FAs, FAMEs and TAGs using BEH 2-
EP, BEH, BSS C18 and Torus 1-AA columns 
The choice of a proper organic modifier was another important factor to evaluate in order to 
obtain a reliable chromatographic method. Organic modifiers are generally mixed with CO2 to 
change the polarity of the mobile phase (allowing the elution of more polar compounds) and 
prevent interactions between non-functionalized active sites present on the stationary phase 
surface. This is particularly true for FAs, whose acid group exhibit strong interactions with the 
silanol groups at the surface of the packing materials, with consequent production of peak tailing. 
Different organic modifiers were screened, including MeOH, ACN, MeOH with 25 mM ammonium 
acetate and MeOH with 50 mM ammonium acetate and 2% of water. Acetonitrile, compared to 
MeOH, had poor eluting strength, while the addition of ammonium acetate to methanol at a 
concentration of 25 mM led to a significant reduction of peak tailing with improved peak 
resolution and shorter retention times. The increase in the ammonium acetate concentration and 
the addition of small water percentages did not improve either the separation and the peak 
shape; consequently, MeOH with 25 mM ammonium acetate was selected as mobile phase 
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modifier. The significant effect produced by the addition of ammonium acetate on the asymmetry 
factors may be explained by the ability to compete with the analyte for the proton accepting sites 
on the stationary phase. 
In SFC analysis, the effluent coming off the column is mixed with a proper organic make-up solvent 
before entering the ES source. The use of a make-up solvent is crucial, as it is able to stabilize the 
spray formation and improving the ionization efficiency. Different make-up solvents were tested, 
including MeOH with different concentrations of formic acid, ammonium acetate and sodium 
formate. Among these, the most effective was a mixture of MeOH and sodium formate at a 
concentration of 20 µM at a delivery flow rate of 0.45 µL/min. This played a very important role, 
as it forced the formation of the sodium adduct during the detection of TAGs and FAMEs. The use 
of different make-up solvents led to an uncontrolled ionization of these compounds, with 
consequent formation of protonated molecules and adducts with sodium, ammonium and 
potassium. 
Column temperature, backpressure and mobile phase flow rate also play an important role in 
retention behavior in SFC. The increase of the column temperature causes a decrease in the fluid 
density when working at constant back pressure and flow rate, nevertheless the effect on 
retention varies [104]. In this study, column temperature was changed between 40 and 60 °C. 
With the increase of the column temperature, all saturated compounds had longer retention 
times and broadening peaks. It might be due to the decreasing viscosity of the mobile phase and 
the increasing diffusion coefficients of analytes. However, changes of resolution for saturated and 
unsaturated FAMEs were different. The separation factor of unsaturated FAMEs decreased with 
the increase of temperature, and the opposite trend was observed for saturated FAMEs. 
Consequently, the best compromise in terms of resolution and shape of the peaks was reached at 
a column temperature of 45 °C. As regard the backpressure and flow rate, their decrease led to 
longer retention times and peak broadening. Considering that higher flow rate could be obtained 
under lower backpressure, a backpressure of 150 bar and a flow rate of 1.5 mL/min were chosen 
as the optimized separation conditions.  
3.4.2 UHPSFC-MS method for sterol analysis 
Analysis of sterols was performed separately from the other lipid classes. This was related to the 
fact that ES source is not suitable for free sterol ionization [105]. Consequently, in order to avoid 
derivatization of these compounds prior analysis, different approaches based on APCI [106] or 
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APPI [107] are available. In order to make a comparison between these different API techniques, 
single sterol standards and mixtures of them were analyzed by direct infusion using ESI, APCI and 
APPI. Results for ergosterol analysis, as example, are reported in Figure 27. 
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Figure 27. Mass spectra recorded after direct infusion of an ergosterol solution onto ESI, APCI and 
APPI ion sources 
ESI analysis of ergosterol resulted in a relatively low sensitivity and formation of different ions, 
corresponding to the sodium (m/z 419.5) and potassium adducts (m/z 435.4), and cluster with 
solvent molecules (m/z 451.4 and 483.4).  
APCI analysis, on the other hand, resulted in higher sensitivity and formation of only one ion, 
occurred from protonation and consequent loss of water (m/z 379.4) [108]. 
APPI analysis was performed infusing the ergosterol standard dissolved in mixtures MeOH-toluene 
90:10 and 50:50. The use of toluene as dopant is necessary in APPI experiments in order to 
enhance the ionization through electron transfer mechanism [109]. Neat toluene was not used as 
it would have not represented the chromatographic conditions in which MeOH is always present 
in the mobile phase. APPI analysis raised two main points. First, two main ions are formed during 
the ionization process, corresponding to the [M + H - H20]+ (m/z 379.4) and [M]
.+ (m/z 396.5); 
second, the increase in toluene percentage resulted in a sensitivity increase and in a preferential 
formation of [M].+ over [M + H - H20]+ ion. 
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In analogy to the other lipid classes investigated, experiments using standard solutions of sterols 
were performed in order to select the proper separation conditions, based on the choice of 
chromatographic column, mobile phase modifier, make-up solvent, column temperature, 
backpressure and mobile phase flow rate. Figure 28 shows the separation profiles obtained by 
using four different columns; the best performances, in terms of baseline separation and peak 
shape, was obtained by using the Torus 1-AA column. 
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Figure 28. TICC reporting the UHPSFC separation of the tested sterols using BEH 2-EP, BEH, BSS 
C18 and Torus 1-AA columns. The elution order is cholesterol, β-sitosterol, stigmasterol and 
ergosterol 
Furtherly, a comparison between APCI and APPI performances after chromatographic analysis was 
performed. Results showed that peak intensities in TICC is slightly higher for APPI ionization, but 
this is due to the fact that two ions are formed for each compound (Figure 29), while in APCI only 
one occurs. Consequently, as for quantitative analysis it is desirable that only one ion is formed, 
APCI was selected as ionization source for sterol analysis. 
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Figure 29. Separation of sterol mixture using a Torus 1-AA column and APPI as ion source. Two 
ions are formed for each compound, corresponding to [M + H - H2O]+ and [M]
.+ 
3.4.3 UHPSFC-MS method validation 
Under the optimal conditions, the developed UHPSFC-MS method was validated for the different 
tested lipid classes. Results are summarized in Table 13 and Table 14. 
Selectivity was established by injection of single standards and of mixtures of them, in order to 
determinate their retention time. The comparison between standard solutions and samples 
fortified with known amounts of analyte, using SIR detection, showed absence of any interference 
in the matrices. 
Seven-point calibration curves, affording correlation coefficients ≥0.995 for all the analytes, based 
on peak area and without internal standard, were used for the quantification. The calibration 
ranges specific to each tested compound are reported in Table 13, except for TAGs for which no 
calibration curve was established because of lack of single compound standards. 
LOD and LOQ values were determined as the concentrations giving a signal to noise ratio of, 
respectively, 3 and 10. Experimentally determined LODs were in the range 5-50 ng/mL, while LOQs 
ranged from 10 to 100 ng/mL. The LOD and LOQ values for each tested compound are reported in 
Table 13. 
Precision (SD%) and Accuracy (Bias%) values were less than 15% for all the studied compounds. 
These results indicate that the method fulfils the ICH guidelines, being sufficiently precise and 
accurate, and although its use is generally recommended, internal standard is not necessary. 
Precision and accuracy were not determined for TAGs because of lack of single compound 
standards. 
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Table 13. LODs, LOQs and calibration curves for all the studied compounds 
Compound LOD (ng/mL) LOQ (ng/mL) Calibration range (µg/mL) r2 
Decanoic acid 50 100 0.10-10 >0.995 
Valeric acid 20 50 0.10-10 >0.995 
Myristic acid 10 40 0.10-10 >0.995 
Palmitic acid 10 20 0.10-10 >0.995 
Stearic acid 10 20 0.10-10 >0.995 
Arachidic acid 10 20 0.10-10 >0.995 
Methyl decanoate 50 100 0.10-10 >0.995 
Methyl valerate 50 100 0.10-10 >0.995 
Methyl myristate 50 100 0.10-10 >0.995 
Methyl palmitate 50 100 0.10-10 >0.995 
Methyl stearate 50 100 0.10-10 >0.995 
Methyl oleate 5 10 0.01-1 >0.995 
Methyl linoleate 5 10 0.01-1 >0.995 
Methyl linolenate 5 10 0.01-1 >0.995 
16:0/14:0/14:0 10 20 - - 
14:0/14:0/14:0 10 20 - - 
12:0/14:0/14:0 10 20 - - 
Cholesterol 10 30 0.10-10 >0.995 
β-sitosterol 10 30 0.10-10 >0.995 
Stigmasterol 10 30 0.10-10 >0.995 
Ergosterol 10 30 0.10-10 >0.995 
 
3.4.4 UHPLC-QTOF analysis 
The developed and validated UHPSFC-MS method for the analysis of FAMEs, TAGs and FAs was 
compared to well established [110, 111] liquid chromatography methods. This was done in order 
to prove the reliability of the SFC for lipidomic analysis. The results (Figure 25) showed that UHPLC 
separation by means of C18 column and MeOH-Water based mobile phase is able to separate 
compounds within a lipid class. However, FAs (detected in negative ion mode) and FAMEs 
(detected in positive ion mode) have very similar retention times, and consequently they cannot 
be simultaneously analyzed within the same chromatographic run. On the contrary, SFC method is 
able to separate compounds within both a class and different classes of lipids, allowing the 
simultaneous analysis of analytes detected in different ionization modes simply by switching the 
polarity of the ion source within the same run. In addition, the three TAGs tested were eluted 
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after 12 minutes, suggesting that, in order to analyze all TAGs likely occurring in real samples, 
significantly longer chromatographic analysis, compared to UHPSFC, might be required. 
On the other hand, the described UHPLC method revealed to be more suitable than SFC for the 
analysis of SGs. These molecules, differently from sterols, show better ionization using ESI source 
(where they are detected as [M + Na]+) than APCI (where, similarly to their free analogues, the 
predominant positive ion corresponds to the loss of glucose and then water after protonation). 
This is due to the amphipathic nature of SGs, where the presence of the glucoside moiety 
increases the polarity and the response in ESI [112]. All the previously tested SFC columns were 
tried on SGs separation, giving poor results (Figure 30).  
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Figure 30. TICC reporting the UHPSFC separation of the tested SGs using BEH 2-EP, BEH, BSS C18 
and Torus 1-AA columns. 1=cholesteryl glucoside, 2=campesteryl glucoside, 3=stigmasteryl 
glucoside, 4=Δ7-avenasteryl glucoside, 5=Δ5-avenasteryl glucoside, 6=β-sitosteryl glucoside 
Satisfactory chromatographic separation, on the other hand, was achieved using reversed phase 
chromatography, as showed in Figure 31. 
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Figure 31. EIC of the targeted SGs detected as [M + Na]+ ions by ESI-QTOF after UHPLC separation 
using a C18 column 
The order of elution using a C18 column and a mobile phase made of MeOH and water (both 
acidified with 0.2% of formic acid) was Δ7-avenasteryl glucoside (6.70 min), cholesteryl glucoside 
(6.85 min), Δ5-avenasteryl glucoside (6.89 min), campesteryl glucoside (7.21 min), stigmasteryl 
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glucoside (7.32 min), and sitosteryl glucoside (7.86 min). All SGs were separated, except for 
stigmasteryl and campesteryl glucosides, Δ5-avenasteryl, and cholesteryl glucosides, which 
coeluted, but which could still be distinguished by their m/z values. Due to the lack of pure 
standards for all the SGs, quantification of each compound was performed using the calibration 
curve of cholesterol glucoside. The determined LOD and LOQ were, respectively, 10 and 30 ng/mL.  
In conclusion, the use of the UHPLC-QTOF is a very valuable tool for targeted analysis of 
compounds not appropriate for SFC, and for untargeted lipid analysis [113], where 
chromatographic separation, tandem mass spectrometry and accurate mass measurements are 
required in order to confirm the identity of compounds for which the corresponding analytical 
standard is not available. 
3.4.5 Analysis of archaeological samples 
Different extracts from real archaeological samples and artificial cooking hearth were analyzed 
using the methods described above. These extracts were obtained from solid samples throughout 
Soxhlet extraction using Hex (type A sample) or MeOH/Tol (type B sample), according to the 
procedure reported in Paragraph 3.3.6. Over 80 samples were analyzed using the UHPSFC-
ES/APCI-MS methods described above and FT-ICR MS analysis was carried out as well in order to 
confirm the identities of the compounds lacking the respective analytical standard. Figures 32 and 
Figure 33 show the results obtained, respectively, from the analysis of one type A and one type B 
archaeological samples.  
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Figure 32. RIC obtained from the UHPSFC-MS analysis of a type A archaeological sample, showing 
its composition in terms of TAGs, FAs (A panel) and sterols (B panel). 
The results obtained from the analysis of type A samples showed that the extraction procedure 
using hexane was able to recover detectable amounts of TAGs, FAs and sterols (mainly cholesterol 
and β-sitosterol). The detected TAGs, identified by the expected m/z value and chromatographic 
behavior, were both saturated and unsaturated and in a range of chain lengths and double bonds 
ranging from 44:0 to 54:6. The FA composition was very interesting as, according to the retention 
time and the m/z value of the standard references, it showed the presence of compounds ranging 
from C10:0 to C20:0, with also C18:1, C18:2 and C18:3. Among these, palmitic acid and stearic acid 
were the most abundant, followed by arachidic acid, oleic acid and myristic acid. 
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Figure 33. RIC obtained from the UHPSFC-MS analysis of a type B archaeological sample, showing 
its composition in terms of TAGs, FAs (A panel) and sterols (B panel) 
The results obtained from the analysis of type B samples showed that the extraction procedure 
using Tol:MeOH was able to recover very low amounts of TAGs and sterols, but higher quantities 
of FAs, compared to the corresponding type A extract. 
It is important to keep into account that the composition of these samples might be very variable, 
therefore is not possible to easily extent the above considerations to all the samples analyzed 
without a proper evaluation of the recorded data. Indeed, many of these samples belong to 
different geographic areas, archaeological sites and historical age. For this reason, in order to 
avoid any misleading assumptions, the data interpretations must be carefully carried out 
accordingly to these variables.
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3.5 Conclusions 
Organic residue analysis can address archaeological questions regarding diet and subsistence 
practices, as well as the ancient trade of goods and raw materials, technology (including vessel 
production, use and provenance), resource acquisition/exploitation, and the domestication of 
plants and animals, among other issues. The majority of organic residue analyses are carried out 
on absorbed organic residues from ceramic vessels. These residues generally come from the 
original contents either stored or processed in the vessels, either from use for a single product, or 
from an accumulation of individual uses in a vessel over its life history. Organic residues survive 
widely in association with ceramics and can endure over considerable timescales. 
Conversely, the analysis performed on excavated hearth-material have been poorly explored, thus 
they represent an intriguing and comparable alternative. Indeed, to the best of knowledge, only 
two papers have been reported so far about this kind of material [114, 115]. Unfortunately, none 
of them had as primary goal the identification of foodstuff related the cooking practices, then it is 
still completely unknown whether complex dietary biomarkers, namely lipids, can survive and 
persist within the charcoal, ash or inorganic base of a hearth in detectable levels. 
This project has been developed with the aim of identifying the organic pyrolysis products that 
reside within a hearth following the cooking of food. This would provide evidence to ascertain 
whether hearth-ash is undervalued in its potential role within archaeological ORA. With this aim, 
different analytical approaches have been developed for the target analysis of specific lipid 
classes, namely FAMEs, FAs, TAGs, sterols and SGs, in order to find the best instrumental 
conditions for their analysis. The choice to proceed with a target approach toward selected lipid 
classes was due to the necessity of improving the method performances, especially selectivity and 
sensitivity, in order to detect and identify with sufficient confidence low concentrations of the 
expected biomarkers. 
The developed methods, based on the combination of chromatography, low resolution and high-
resolution mass spectrometry, have been applied to the analysis of several archaeological sample 
extracts and proved to be effective for the detection and identification of biomarkers belonging to 
the expected lipid families. With great surprise, more compounds than expected have been found, 
especially for what concerns (poli)unsaturated FAs/TAGs that are known for being less stable than 
their saturated analogues. These results have great importance in the area of the archaeological 
sciences, as they open the lead for the investigation of a field that has been completely ignored so 
 94 
far. Although more accurate insights and data interpretation are needed for confirming these 
preliminary results, hearth-material has shown to hold great promise for future ORA applications. 
Future work might involve the extension of these methods to other classes of biomarkers so that it 
could be possible to distinguish between the food types cooked on hearths, providing new insights 
in the diet habits of Neanderthal men or, more generally, addressing other issues not yet fully 
elucidated.    
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